| virus |
work |
| Human coronavirus 229E (edit) |
A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets (edit) |
| Human coronavirus 229E (edit) |
ADP-ribose-1"-phosphatase activities of the human coronavirus 229E and SARS coronavirus X domains (edit) |
| Human coronavirus 229E (edit) |
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses (edit) |
| Human coronavirus 229E (edit) |
Biochemical and immunological studies of nucleocapsid proteins of severe acute respiratory syndrome and 229E human coronaviruses. (edit) |
| Human coronavirus 229E (edit) |
Comparative host gene transcription by microarray analysis early after infection of the Huh7 cell line by SARS coronavirus and human coronavirus 229E. (edit) |
| Human coronavirus 229E (edit) |
Comparative host gene transcription by microarray analysis early after infection of the Huh7 cell line by severe acute respiratory syndrome coronavirus and human coronavirus 229E. (edit) |
| Human coronavirus 229E (edit) |
Coronavirus replication-transcription complex: Vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit (edit) |
| Human coronavirus 229E (edit) |
Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, Japan (edit) |
| Human coronavirus 229E (edit) |
Exaggerated risk of transmission of COVID-19 by fomites (edit) |
| Human coronavirus 229E (edit) |
Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients (edit) |
| Human coronavirus 229E (edit) |
Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway (edit) |
| Human coronavirus 229E (edit) |
Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease (edit) |
| Human coronavirus 229E (edit) |
Rebuttal to Overinterpretation of the antiviral results for human coronavirus 229E (HCoV-229E) relative to severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) by Rowpar Pharmaceuticals (edit) |
| Human coronavirus 229E (edit) |
Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. (edit) |
| Human coronavirus 229E (edit) |
The ADP-ribose-1''-monophosphatase domains of severe acute respiratory syndrome coronavirus and human coronavirus 229E mediate resistance to antiviral interferon responses (edit) |
| Human coronavirus 229E (edit) |
The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways (edit) |
| Human coronavirus HKU1 (edit) |
Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, Japan (edit) |
| Human coronavirus HKU1 (edit) |
Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China (edit) |
| Human coronavirus HKU1 (edit) |
The novel human coronaviruses NL63 and HKU1. (edit) |
| Human coronavirus HKU1 (edit) |
[Development and comparison of real-time and conventional RT-PCR assay for detection of human coronavirus NL63 and HKU1]. (edit) |
| Human coronavirus OC43 (edit) |
An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus (edit) |
| Human coronavirus OC43 (edit) |
Characterization of human coronavirus OC43 and human coronavirus NL63 infections among hospitalized children <5 years of age. (edit) |
| Human coronavirus OC43 (edit) |
Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity (edit) |
| Human coronavirus OC43 (edit) |
Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations (edit) |
| Human coronavirus OC43 (edit) |
Coronavirus isolates SK and SD from multiple sclerosis patients are serologically related to murine coronaviruses A59 and JHM and human coronavirus OC43, but not to human coronavirus 229E. (edit) |
| Human coronavirus OC43 (edit) |
Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, Japan (edit) |
| Human coronavirus OC43 (edit) |
Exaggerated risk of transmission of COVID-19 by fomites (edit) |
| Human coronavirus OC43 (edit) |
False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike p (edit) |
| Human coronavirus OC43 (edit) |
Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients (edit) |
| Human coronavirus OC43 (edit) |
Survival of human coronaviruses 229E and OC43 in suspension and after drying on surfaces: a possible source of hospital-acquired infections (edit) |
| Human coronavirus OC43 (edit) |
The dominance of human coronavirus OC43 and NL63 infections in infants (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
MOV10 Helicase Interacts with Coronavirus Nucleocapsid Protein and Has Antiviral Activity (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Medusa's ugly head again: from SARS to MERS-CoV. (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Middle East respiratory syndrome: SARS redux? (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Risks to healthcare workers with emerging diseases: lessons from MERS-CoV, Ebola, SARS, and avian flu. (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
SARS-CoV-2, SARS-CoV and MERS-CoV encode circular RNAs of spliceosome-independent origin (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2 (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
The human pandemic coronaviruses on the show: The spike glycoprotein as the main actor in the coronaviruses play (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy (edit) |
| Middle East respiratory syndrome coronavirus (edit) |
Travel implications of emerging coronaviruses: SARS and MERS-CoV. (edit) |
| SARS-CoV-2 (edit) |
A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets (edit) |
| SARS-CoV-2 (edit) |
A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease (edit) |
| SARS-CoV-2 (edit) |
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) (edit) |
| SARS-CoV-2 (edit) |
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 (edit) |
| SARS-CoV-2 (edit) |
Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1 (edit) |
| SARS-CoV-2 (edit) |
Age-Related Differences in Immunological Responses to SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Autopsy in suspected COVID-19 cases (edit) |
| SARS-CoV-2 (edit) |
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses (edit) |
| SARS-CoV-2 (edit) |
Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein (edit) |
| SARS-CoV-2 (edit) |
Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs (edit) |
| SARS-CoV-2 (edit) |
COVID-19 pneumonia: what has CT taught us? (edit) |
| SARS-CoV-2 (edit) |
Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR (edit) |
| SARS-CoV-2 (edit) |
Chemokine Regulation During Epidemic Coronavirus Infection (edit) |
| SARS-CoV-2 (edit) |
Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past (edit) |
| SARS-CoV-2 (edit) |
Commentary: Lethal Pneumonia Cases in Mojiang Miners (2012) and the Mineshaft Could Provide Important Clues to the Origin of SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Comparative dynamic aerosol efficiencies of three emergent coronaviruses and the unusual persistence of SARS-CoV-2 in aerosol suspensions (edit) |
| SARS-CoV-2 (edit) |
Comparative protein structure network analysis on 3CLpro from SARS-CoV-1 and SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Comparing the Binding Interactions in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV (edit) |
| SARS-CoV-2 (edit) |
Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option (edit) |
| SARS-CoV-2 (edit) |
Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Coronavirus replication-transcription complex: Vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit (edit) |
| SARS-CoV-2 (edit) |
Developing antibody tests for SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Direct Comparison of N-Glycans and Their Isomers Derived from Spike Glycoprotein 1 of MERS-CoV, SARS-CoV-1, and SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV (edit) |
| SARS-CoV-2 (edit) |
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD (edit) |
| SARS-CoV-2 (edit) |
Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 (edit) |
| SARS-CoV-2 (edit) |
Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic (edit) |
| SARS-CoV-2 (edit) |
Exaggerated risk of transmission of COVID-19 by fomites (edit) |
| SARS-CoV-2 (edit) |
Exploiting Connections for Viral Replication (edit) |
| SARS-CoV-2 (edit) |
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes (edit) |
| SARS-CoV-2 (edit) |
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses (edit) |
| SARS-CoV-2 (edit) |
Head and neck survivorship care in the times of the SARS-CoV-2 pandemic (edit) |
| SARS-CoV-2 (edit) |
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa (edit) |
| SARS-CoV-2 (edit) |
Identification and characterization of circRNAs encoded by MERS-CoV, SARS-CoV-1 and SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches (edit) |
| SARS-CoV-2 (edit) |
Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Increased Incidence, Morbidity, and Mortality in Human Coronavirus NL63 Associated with ACE Inhibitor Therapy and Implication in SARS-CoV-2 (COVID-19) (edit) |
| SARS-CoV-2 (edit) |
Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV (edit) |
| SARS-CoV-2 (edit) |
Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 (edit) |
| SARS-CoV-2 (edit) |
Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins (edit) |
| SARS-CoV-2 (edit) |
Long-Term Health Consequences of SARS-CoV-2: Assumptions Based on SARS-CoV-1 and MERS-CoV Infections (edit) |
| SARS-CoV-2 (edit) |
MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges (edit) |
| SARS-CoV-2 (edit) |
MOV10 Helicase Interacts with Coronavirus Nucleocapsid Protein and Has Antiviral Activity (edit) |
| SARS-CoV-2 (edit) |
Mechanisms of Coronavirus Nsp1-Mediated Control of Host and Viral Gene Expression (edit) |
| SARS-CoV-2 (edit) |
Mechanistic insights of host cell fusion of SARS-CoV-1 and SARS-CoV-2 from atomic resolution structure and membrane dynamics (edit) |
| SARS-CoV-2 (edit) |
Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV (edit) |
| SARS-CoV-2 (edit) |
Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV (edit) |
| SARS-CoV-2 (edit) |
Mystery deepens over animal source of coronavirus (edit) |
| SARS-CoV-2 (edit) |
N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition (edit) |
| SARS-CoV-2 (edit) |
Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virions (edit) |
| SARS-CoV-2 (edit) |
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV (edit) |
| SARS-CoV-2 (edit) |
Novel coronavirus SARS-CoV-2 and COVID-19. Practice recommendations for obstetric anaesthesia: what we have learned thus far (edit) |
| SARS-CoV-2 (edit) |
Ocular tropism of coronavirus (CoVs): a comparison of the interaction between the animal-to-human transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye (edit) |
| SARS-CoV-2 (edit) |
On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2 (edit) |
| SARS-CoV-2 (edit) |
On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2 (edit) |
| SARS-CoV-2 (edit) |
Palindromic target site identification in SARS-CoV-2, MERS-CoV and SARS-CoV-1 by adopting CRISPR-Cas technique (edit) |
| SARS-CoV-2 (edit) |
Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’ attack (edit) |
| SARS-CoV-2 (edit) |
Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway (edit) |
| SARS-CoV-2 (edit) |
Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review (edit) |
| SARS-CoV-2 (edit) |
Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1 (edit) |
| SARS-CoV-2 (edit) |
Preparing for emerging respiratory pathogens such as SARS-CoV, MERS-CoV, and SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Rapid Review of SARS-CoV-1 and SARS-CoV-2 Viability, Susceptibility to Treatment, and the Disinfection and Reuse of PPE, Particularly Filtering Facepiece Respirators (edit) |
| SARS-CoV-2 (edit) |
Rebuttal to Overinterpretation of the antiviral results for human coronavirus 229E (HCoV-229E) relative to severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) by Rowpar Pharmaceuticals (edit) |
| SARS-CoV-2 (edit) |
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus (edit) |
| SARS-CoV-2 (edit) |
Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19' (edit) |
| SARS-CoV-2 (edit) |
SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling (edit) |
| SARS-CoV-2 (edit) |
SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential (edit) |
| SARS-CoV-2 (edit) |
SARS-CoV-2's claimed natural origin is undermined by issues with genome sequences of its relative strains: Coronavirus sequences RaTG13, MP789 and RmYN02 raise multiple questions to be critically addressed by the scientific community (edit) |
| SARS-CoV-2 (edit) |
SARS-CoV-2, SARS-CoV and MERS-CoV encode circular RNAs of spliceosome-independent origin (edit) |
| SARS-CoV-2 (edit) |
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis (edit) |
| SARS-CoV-2 (edit) |
SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway (edit) |
| SARS-CoV-2 (edit) |
Sarbecovirus comparative genomics elucidates gene content of SARS-CoV-2 and functional impact of COVID-19 pandemic mutations (edit) |
| SARS-CoV-2 (edit) |
Serial co-expression analysis of host factors from SARS-CoV viruses highly converges with former high-throughput screenings and proposes key regulators (edit) |
| SARS-CoV-2 (edit) |
Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses (edit) |
| SARS-CoV-2 (edit) |
Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group (edit) |
| SARS-CoV-2 (edit) |
Shifts in global bat diversity suggest a possible role of climate change in the emergence of SARS-CoV-1 and SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Structure and immune recognition of the porcine epidemic diarrhea virus spike protein (edit) |
| SARS-CoV-2 (edit) |
The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner (edit) |
| SARS-CoV-2 (edit) |
The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways (edit) |
| SARS-CoV-2 (edit) |
The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis (edit) |
| SARS-CoV-2 (edit) |
The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
The human pandemic coronaviruses on the show: The spike glycoprotein as the main actor in the coronaviruses play (edit) |
| SARS-CoV-2 (edit) |
The proximal origin of SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 (edit) |
| SARS-CoV-2 (edit) |
Topological Analysis for Sequence Variability: Case Study on more than 2K SARS-CoV-2 sequences of COVID-19 infected 54 countries in comparison with SARS-CoV-1 and MERS-CoV (edit) |
| SARS-CoV-2 (edit) |
[Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.] (edit) |
| SARS-CoV-2 (edit) |
[Source of the COVID-19 pandemic: ecology and genetics of coronaviruses (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (subgenus Sarbecovirus), and MERS-CoV (subgenus Merbecovirus).] (edit) |
| SARSr-CoV (edit) |
1H, 13C and 15N resonance assignments of SARS-CoV main protease N-terminal domain. (edit) |
| SARSr-CoV (edit) |
2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV). (edit) |
| SARSr-CoV (edit) |
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity (edit) |
| SARSr-CoV (edit) |
A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening. (edit) |
| SARSr-CoV (edit) |
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice (edit) |
| SARSr-CoV (edit) |
A Novel Chemical Compound for Inhibition of SARS Coronavirus Helicase. (edit) |
| SARSr-CoV (edit) |
A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence (edit) |
| SARSr-CoV (edit) |
A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro. (edit) |
| SARSr-CoV (edit) |
A climatologic investigation of the SARS-CoV outbreak in Beijing, China. (edit) |
| SARSr-CoV (edit) |
A convenient cell fusion assay for the study of SARS-CoV entry and inhibition. (edit) |
| SARSr-CoV (edit) |
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury (edit) |
| SARSr-CoV (edit) |
A decade after SARS: strategies for controlling emerging coronaviruses (edit) |
| SARSr-CoV (edit) |
A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage (edit) |
| SARSr-CoV (edit) |
A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. (edit) |
| SARSr-CoV (edit) |
A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide (edit) |
| SARSr-CoV (edit) |
A fluorogenic peptide containing the processing site of human SARS corona virus S-protein: kinetic evaluation and NMR structure elucidation. (edit) |
| SARSr-CoV (edit) |
A genome sequence of novel SARS-CoV isolates: the genotype, GD-Ins29, leads to a hypothesis of viral transmission in South China. (edit) |
| SARSr-CoV (edit) |
A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. (edit) |
| SARSr-CoV (edit) |
A human SARS-CoV neutralizing antibody against epitope on S2 protein (edit) |
| SARSr-CoV (edit) |
A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection (edit) |
| SARSr-CoV (edit) |
A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2. (edit) |
| SARSr-CoV (edit) |
A monomer-dimer nanoswitch that mimics the working principle of the SARS-CoV 3CLpro enzyme controls copper-catalysed cyclopropanation. (edit) |
| SARSr-CoV (edit) |
A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice (edit) |
| SARSr-CoV (edit) |
A network integration approach to predict conserved regulators related to pathogenicity of influenza and SARS-CoV respiratory viruses (edit) |
| SARSr-CoV (edit) |
A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus (edit) |
| SARSr-CoV (edit) |
A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo (edit) |
| SARSr-CoV (edit) |
A new nucleotide-composition based fingerprint of SARS-CoV with visualization analysis (edit) |
| SARSr-CoV (edit) |
A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication (edit) |
| SARSr-CoV (edit) |
A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor. (edit) |
| SARSr-CoV (edit) |
A novel fingerprint map for detecting SARS-CoV. (edit) |
| SARSr-CoV (edit) |
A novel subset of putative stem/progenitor CD34+Oct-4+ cells is the major target for SARS coronavirus in human lung. (edit) |
| SARSr-CoV (edit) |
A one step quantitative RT-PCR for detection of SARS coronavirus with an internal control for PCR inhibitors. (edit) |
| SARSr-CoV (edit) |
A preliminary report of SARS coronavirus specific RNA in SARS convalescents and medical person (edit) |
| SARSr-CoV (edit) |
A putative diacidic motif in the SARS-CoV ORF6 protein influences its subcellular localization and suppression of expression of co-transfected expression constructs. (edit) |
| SARSr-CoV (edit) |
A rapid point of care immunoswab assay for SARS-CoV detection (edit) |
| SARSr-CoV (edit) |
A real-time PCR assay for bat SARS-like coronavirus detection and its application to Italian greater horseshoe bat faecal sample surveys. (edit) |
| SARSr-CoV (edit) |
A real-time PCR for SARS-coronavirus incorporating target gene pre-amplification (edit) |
| SARSr-CoV (edit) |
A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice (edit) |
| SARSr-CoV (edit) |
A simple and rapid approach for screening of SARS-coronavirus genotypes: an evaluation study (edit) |
| SARSr-CoV (edit) |
A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies (edit) |
| SARSr-CoV (edit) |
A strategy for searching antigenic regions in the SARS-CoV spike protein. (edit) |
| SARSr-CoV (edit) |
A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters (edit) |
| SARSr-CoV (edit) |
A study on antigenicity and receptor-binding ability of fragment 450-650 of the spike protein of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. (edit) |
| SARSr-CoV (edit) |
A three-stemmed mRNA pseudoknot in the SARS coronavirus frameshift signal (edit) |
| SARSr-CoV (edit) |
A throat lozenge containing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus, influenza A and SARS-CoV (edit) |
| SARSr-CoV (edit) |
A universal microarray for detection of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
ACE2: from vasopeptidase to SARS virus receptor (edit) |
| SARSr-CoV (edit) |
Accelerated induction of apoptosis in insect cells by baculovirus-expressed SARS-CoV membrane protein (edit) |
| SARSr-CoV (edit) |
Accumulation of recombinant SARS-CoV spike protein in plant cytosol and chloroplasts indicate potential for development of plant-derived oral vaccines (edit) |
| SARSr-CoV (edit) |
Acquisition of new protein domains by coronaviruses: analysis of overlapping genes coding for proteins N and 9b in SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups (edit) |
| SARSr-CoV (edit) |
Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats (edit) |
| SARSr-CoV (edit) |
Aetiology: Koch's postulates fulfilled for SARS virus (edit) |
| SARSr-CoV (edit) |
Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model (edit) |
| SARSr-CoV (edit) |
Allelic Variation in the Toll-Like Receptor Adaptor Protein Ticam2 Contributes to SARS-Coronavirus Pathogenesis in Mice. (edit) |
| SARSr-CoV (edit) |
Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection. (edit) |
| SARSr-CoV (edit) |
Amino acids 1 to 422 of the spike protein of SARS associated coronavirus are required for induction of cyclooxygenase-2. (edit) |
| SARSr-CoV (edit) |
Amino acids 15-28 in the ectodomain of SARS coronavirus 3a protein induces neutralizing antibodies (edit) |
| SARSr-CoV (edit) |
Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. (edit) |
| SARSr-CoV (edit) |
An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus (edit) |
| SARSr-CoV (edit) |
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. (edit) |
| SARSr-CoV (edit) |
An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus (edit) |
| SARSr-CoV (edit) |
An atypical RNA pseudoknot stimulator and an upstream attenuation signal for -1 ribosomal frameshifting of SARS coronavirus (edit) |
| SARSr-CoV (edit) |
An efficient RNA-cleaving DNA enzyme can specifically target the 5'-untranslated region of severe acute respiratory syndrome associated coronavirus (SARS-CoV). (edit) |
| SARSr-CoV (edit) |
An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors (edit) |
| SARSr-CoV (edit) |
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
An immunofluorescence assay for the detection of SARS associated coronavirus antibody based on recombinant nucleocapsid antigen and its application (edit) |
| SARSr-CoV (edit) |
An immunosuppressed Syrian golden hamster model for SARS-CoV infection (edit) |
| SARSr-CoV (edit) |
An initial investigation of the association between the SARS outbreak and weather: with the view of the environmental temperature and its variation (edit) |
| SARSr-CoV (edit) |
An oral mucosal DNA vaccine for SARS coronavirus infections. (edit) |
| SARSr-CoV (edit) |
An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: structures, functions and drug development (edit) |
| SARSr-CoV (edit) |
Analysis of SARS-CoV receptor activity of ACE2 orthologs (edit) |
| SARSr-CoV (edit) |
Analysis of synonymous codon usage in SARS Coronavirus and other viruses in the Nidovirales. (edit) |
| SARSr-CoV (edit) |
Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry. (edit) |
| SARSr-CoV (edit) |
Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Animal coronavirus vaccines: lessons for SARS. (edit) |
| SARSr-CoV (edit) |
Animal models and vaccines for SARS-CoV infection. (edit) |
| SARSr-CoV (edit) |
Animal models for SARS and MERS coronaviruses (edit) |
| SARSr-CoV (edit) |
Animal origins of SARS coronavirus: possible links with the international trade in small carnivores (edit) |
| SARSr-CoV (edit) |
Animal reservoirs for SARS-like coronavirus in southern China. (edit) |
| SARSr-CoV (edit) |
Animal-to-human SARS-associated coronavirus transmission? (edit) |
| SARSr-CoV (edit) |
Anti-HIV, anti-poxvirus, and anti-SARS activity of a nontoxic, acidic plant extract from the Trifollium species Secomet-V/anti-vac suggests that it contains a novel broad-spectrum antiviral. (edit) |
| SARSr-CoV (edit) |
Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. (edit) |
| SARSr-CoV (edit) |
Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts. (edit) |
| SARSr-CoV (edit) |
Anti-SARS coronavirus agents: a patent review (2008 - present). (edit) |
| SARSr-CoV (edit) |
Anti-SARS virus antibody responses against human SARS-associated coronavirus and animal SARS-associated coronavirus-like virus. (edit) |
| SARSr-CoV (edit) |
Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. (edit) |
| SARSr-CoV (edit) |
Anti-SARS-CoV activity of nucleoside analogs having 6-chloropurine as a nucleobase. (edit) |
| SARSr-CoV (edit) |
Anti-SARS-CoV immunoglobulin G in healthcare workers, Guangzhou, China (edit) |
| SARSr-CoV (edit) |
Anti-frameshifting ligand reduces the conformational plasticity of the SARS virus pseudoknot. (edit) |
| SARSr-CoV (edit) |
Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. (edit) |
| SARSr-CoV (edit) |
Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. (edit) |
| SARSr-CoV (edit) |
Antibodies to SARS coronavirus in civets (edit) |
| SARSr-CoV (edit) |
Antibodies to SARS-like virus hint at repeated infections. (edit) |
| SARSr-CoV (edit) |
Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening (edit) |
| SARSr-CoV (edit) |
Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. (edit) |
| SARSr-CoV (edit) |
Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. (edit) |
| SARSr-CoV (edit) |
Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. (edit) |
| SARSr-CoV (edit) |
Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. (edit) |
| SARSr-CoV (edit) |
Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. (edit) |
| SARSr-CoV (edit) |
Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity. (edit) |
| SARSr-CoV (edit) |
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins (edit) |
| SARSr-CoV (edit) |
Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. (edit) |
| SARSr-CoV (edit) |
Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein. (edit) |
| SARSr-CoV (edit) |
Antigenic cross-reactivity between the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus and polyclonal antisera of antigenic group I animal coronaviruses: implication for SARS diagnosis. (edit) |
| SARSr-CoV (edit) |
Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells (edit) |
| SARSr-CoV (edit) |
Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. (edit) |
| SARSr-CoV (edit) |
Antisense downregulation of SARS-CoV gene expression in Vero E6 cells. (edit) |
| SARSr-CoV (edit) |
Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS). (edit) |
| SARSr-CoV (edit) |
Antiviral drug discovery against SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Antiviral treatment of SARS: can we draw any conclusions? (edit) |
| SARSr-CoV (edit) |
Apoptosis induced by the SARS-associated coronavirus in Vero cells is replication-dependent and involves caspase. (edit) |
| SARSr-CoV (edit) |
Application of bioinformatics in search for cleavable peptides of SARS-CoV M(pro) and chemical modification of octapeptides (edit) |
| SARSr-CoV (edit) |
Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro (edit) |
| SARSr-CoV (edit) |
Applying lessons from SARS to a newly identified coronavirus. (edit) |
| SARSr-CoV (edit) |
Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase. (edit) |
| SARSr-CoV (edit) |
Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV). (edit) |
| SARSr-CoV (edit) |
Assembling the SARS-CoV genome -- new method based on graph theoretical approach. (edit) |
| SARSr-CoV (edit) |
Asymptomatic SARS coronavirus infection among healthcare workers, Singapore (edit) |
| SARSr-CoV (edit) |
Asymptomatic animal traders prove positive for SARS virus. (edit) |
| SARSr-CoV (edit) |
Attachment factor and receptor engagement of SARS coronavirus and human coronavirus NL63. (edit) |
| SARSr-CoV (edit) |
Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase. (edit) |
| SARSr-CoV (edit) |
Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. (edit) |
| SARSr-CoV (edit) |
Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection. (edit) |
| SARSr-CoV (edit) |
Automated extraction protocol for quantification of SARS-coronavirus RNA in serum: an evaluation study. (edit) |
| SARSr-CoV (edit) |
Baculovirus surface display of SARS coronavirus (SARS-CoV) spike protein and immunogenicity of the displayed protein in mice models (edit) |
| SARSr-CoV (edit) |
Bat cave solves mystery of deadly SARS virus - and suggests new outbreak could occur. (edit) |
| SARSr-CoV (edit) |
Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond (edit) |
| SARSr-CoV (edit) |
Bats and emerging zoonoses: henipaviruses and SARS. (edit) |
| SARSr-CoV (edit) |
Bats are natural reservoirs of SARS-like coronaviruses (edit) |
| SARSr-CoV (edit) |
Bats as animal reservoirs for the SARS coronavirus: hypothesis proved after 10 years of virus hunting. (edit) |
| SARSr-CoV (edit) |
Bcl-2 inhibits the caspase-dependent apoptosis induced by SARS-CoV without affecting virus replication kinetics. (edit) |
| SARSr-CoV (edit) |
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. (edit) |
| SARSr-CoV (edit) |
Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar-H+ ATPase G1 subunit (edit) |
| SARSr-CoV (edit) |
Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. (edit) |
| SARSr-CoV (edit) |
Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. (edit) |
| SARSr-CoV (edit) |
Bioinformatics analysis of SARS coronavirus genome polymorphism (edit) |
| SARSr-CoV (edit) |
Bioinformatics research on the SARS coronavirus (SARS_CoV) in China (edit) |
| SARSr-CoV (edit) |
Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Bismuth complexes inhibit the SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice. (edit) |
| SARSr-CoV (edit) |
Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway (edit) |
| SARSr-CoV (edit) |
CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein. (edit) |
| SARSr-CoV (edit) |
Candidate genes associated with susceptibility for SARS-coronavirus (edit) |
| SARSr-CoV (edit) |
Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus (edit) |
| SARSr-CoV (edit) |
Cellular entry of the SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection (edit) |
| SARSr-CoV (edit) |
Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Challenges presented by MERS corona virus, and SARS corona virus to global health (edit) |
| SARSr-CoV (edit) |
Changing virulence of the SARS virus: the epidemiological evidence. (edit) |
| SARSr-CoV (edit) |
Characterisation of animal angiotensin-converting enzyme 2 receptors and use of pseudotyped virus to correlate receptor binding with susceptibility of SARS-CoV infection. (edit) |
| SARSr-CoV (edit) |
Characterization and application of monoclonal antibodies against N protein of SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Characterization and inhibition of SARS-coronavirus main protease (edit) |
| SARSr-CoV (edit) |
Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. (edit) |
| SARSr-CoV (edit) |
Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection (edit) |
| SARSr-CoV (edit) |
Characterization of cytotoxic T-lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine expressing the RGD-integrin-binding motif. (edit) |
| SARSr-CoV (edit) |
Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. (edit) |
| SARSr-CoV (edit) |
Characterization of monoclonal antibody against SARS coronavirus nucleocapsid antigen and development of an antigen capture ELISA. (edit) |
| SARSr-CoV (edit) |
Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). (edit) |
| SARSr-CoV (edit) |
Characterization of persistent SARS-CoV infection in Vero E6 cells (edit) |
| SARSr-CoV (edit) |
Characterization of protein-protein interactions between the nucleocapsid protein and membrane protein of the SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro (edit) |
| SARSr-CoV (edit) |
Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. (edit) |
| SARSr-CoV (edit) |
Characterization of viral proteins encoded by the SARS-coronavirus genome. (edit) |
| SARSr-CoV (edit) |
Characterizing 56 complete SARS-CoV S-gene sequences from Hong Kong. (edit) |
| SARSr-CoV (edit) |
Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. (edit) |
| SARSr-CoV (edit) |
Chicken single-chain variable fragments against the SARS-CoV spike protein. (edit) |
| SARSr-CoV (edit) |
Children's vaccines do not induce cross reactivity against SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread (edit) |
| SARSr-CoV (edit) |
Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity (edit) |
| SARSr-CoV (edit) |
Clinical evaluation of real-time PCR assays for rapid diagnosis of SARS coronavirus during outbreak and post-epidemic periods (edit) |
| SARSr-CoV (edit) |
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study (edit) |
| SARSr-CoV (edit) |
Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy (edit) |
| SARSr-CoV (edit) |
Cloning, expression, and purification of the nucleocapsid protein of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Cloning, sequencing, expression, and purification of SARS-associated coronavirus nucleocapsid protein for serodiagnosis of SARS. (edit) |
| SARSr-CoV (edit) |
Combination of functionalized nanoparticles and polymerase chain reaction-based method for SARS-CoV gene detection. (edit) |
| SARSr-CoV (edit) |
Comparative analysis of the SARS coronavirus genome: a good start to a long journey (edit) |
| SARSr-CoV (edit) |
Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model. (edit) |
| SARSr-CoV (edit) |
Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. (edit) |
| SARSr-CoV (edit) |
Comparative host gene transcription by microarray analysis early after infection of the Huh7 cell line by SARS coronavirus and human coronavirus 229E. (edit) |
| SARSr-CoV (edit) |
Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene. (edit) |
| SARSr-CoV (edit) |
Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques (edit) |
| SARSr-CoV (edit) |
Comparative study of clinical characteristics and prognosis of clinically diagnosed SARS patients with positive and negative serum SARS coronavirus-specific antibodies test (edit) |
| SARSr-CoV (edit) |
Comparison of immunoglobulin G responses to the spike and nucleocapsid proteins of severe acute respiratory syndrome (SARS) coronavirus in patients with SARS (edit) |
| SARSr-CoV (edit) |
Complete genome sequences of the SARS-CoV: the BJ Group (Isolates BJ01-BJ04). (edit) |
| SARSr-CoV (edit) |
Comprehensive antibody epitope mapping of the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus: insight into the humoral immunity of SARS. (edit) |
| SARSr-CoV (edit) |
Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay. (edit) |
| SARSr-CoV (edit) |
Computational characterization and design of SARS coronavirus receptor recognition and antibody neutralization (edit) |
| SARSr-CoV (edit) |
Concentration and detection of SARS coronavirus in sewage from Xiao Tang Shan Hospital and the 309th Hospital of the Chinese People's Liberation Army. (edit) |
| SARSr-CoV (edit) |
Concentration and detection of SARS coronavirus in sewage from Xiao Tang Shan Hospital and the 309th Hospital. (edit) |
| SARSr-CoV (edit) |
Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein (edit) |
| SARSr-CoV (edit) |
Conference report - II. Investigating new vaccines: SARS. Highlights from the Viral Vaccine Meeting; October 25-28, 2003; Barcelona, Spain. (edit) |
| SARSr-CoV (edit) |
Construction and screening of SARS-CoV S protein-specific phage displayed antigen library (edit) |
| SARSr-CoV (edit) |
Construction of a eukaryotic expression plasmid encoding partial S gene fragments of the SARS-CoV and its potential utility as a DNA vaccine. (edit) |
| SARSr-CoV (edit) |
Construction of a large human scFv library against SARS virus (edit) |
| SARSr-CoV (edit) |
Construction of a non-infectious SARS coronavirus replicon for application in drug screening and analysis of viral protein function. (edit) |
| SARSr-CoV (edit) |
Construction of phage antibody library for Fab fragment from a convalescent patient infected with SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Coordinate induction of IFN-alpha and -gamma by SARS-CoV also in the absence of virus replication. (edit) |
| SARSr-CoV (edit) |
Copious production of SARS-CoV nucleocapsid protein employing codon optimized synthetic gene. (edit) |
| SARSr-CoV (edit) |
Coronaviridae and SARS-associated coronavirus strain HSR1. (edit) |
| SARSr-CoV (edit) |
Coronavirus 3CLpro proteinase cleavage sites: possible relevance to SARS virus pathology (edit) |
| SARSr-CoV (edit) |
Coronavirus in severe acute respiratory syndrome (SARS). (edit) |
| SARSr-CoV (edit) |
Coronavirus outbreak in cheetahs: lessons for SARS. (edit) |
| SARSr-CoV (edit) |
Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development. (edit) |
| SARSr-CoV (edit) |
Coronaviruses post-SARS: update on replication and pathogenesis (edit) |
| SARSr-CoV (edit) |
Correction: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus. (edit) |
| SARSr-CoV (edit) |
Correction: SARS Coronavirus 3b Accessory Protein Modulates Transcriptional Activity of RUNX1b. (edit) |
| SARSr-CoV (edit) |
Correction: Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants. (edit) |
| SARSr-CoV (edit) |
Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. (edit) |
| SARSr-CoV (edit) |
Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases. (edit) |
| SARSr-CoV (edit) |
Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests (edit) |
| SARSr-CoV (edit) |
Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11. (edit) |
| SARSr-CoV (edit) |
Crystal structures reveal an induced-fit binding of a substrate-like Aza-peptide epoxide to SARS coronavirus main peptidase (edit) |
| SARSr-CoV (edit) |
Crystallization and diffraction analysis of the SARS coronavirus nsp10-nsp16 complex (edit) |
| SARSr-CoV (edit) |
Crystallization and preliminary crystallographic analysis of the heptad-repeat complex of SARS coronavirus spike protein. (edit) |
| SARSr-CoV (edit) |
Cxcl16 interact with SARS-CoV N protein in and out cell (edit) |
| SARSr-CoV (edit) |
Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections (edit) |
| SARSr-CoV (edit) |
Date of origin of the SARS coronavirus strains (edit) |
| SARSr-CoV (edit) |
Deciphering the biosynthetic codes for the potent anti-SARS-CoV cyclodepsipeptide valinomycin in Streptomyces tsusimaensis ATCC 15141. (edit) |
| SARSr-CoV (edit) |
Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein (edit) |
| SARSr-CoV (edit) |
Derivation of a novel SARS-coronavirus replicon cell line and its application for anti-SARS drug screening (edit) |
| SARSr-CoV (edit) |
Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction. (edit) |
| SARSr-CoV (edit) |
Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease (edit) |
| SARSr-CoV (edit) |
Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. (edit) |
| SARSr-CoV (edit) |
Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety. (edit) |
| SARSr-CoV (edit) |
Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain (edit) |
| SARSr-CoV (edit) |
Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors (edit) |
| SARSr-CoV (edit) |
Design, synthesis and screening of antisense peptide based combinatorial peptide libraries towards an aromatic region of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study. (edit) |
| SARSr-CoV (edit) |
Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. (edit) |
| SARSr-CoV (edit) |
Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein. (edit) |
| SARSr-CoV (edit) |
Detection and monitoring of SARS coronavirus in the plasma and peripheral blood lymphocytes of patients with severe acute respiratory syndrome. (edit) |
| SARSr-CoV (edit) |
Detection for severe acute respiratory syndrome (SARS) coronavirus RNA in stool of SARS patients (edit) |
| SARSr-CoV (edit) |
Detection of SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. (edit) |
| SARSr-CoV (edit) |
Detection of SARS coronavirus in humans and animals by conventional and quantitative (real time) reverse transcription polymerase chain reactions. (edit) |
| SARSr-CoV (edit) |
Detection of SARS coronavirus in patients with severe acute respiratory syndrome by conventional and real-time quantitative reverse transcription-PCR assays. (edit) |
| SARSr-CoV (edit) |
Detection of SARS coronavirus in patients with suspected SARS (edit) |
| SARSr-CoV (edit) |
Detection of SARS coronavirus in plasma by real-time RT-PCR. (edit) |
| SARSr-CoV (edit) |
Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis (edit) |
| SARSr-CoV (edit) |
Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. (edit) |
| SARSr-CoV (edit) |
Detection of antibodies against SARS-CoV in serum from SARS-infected donors with ELISA and Western blot. (edit) |
| SARSr-CoV (edit) |
Detection of novel SARS-like and other coronaviruses in bats from Kenya (edit) |
| SARSr-CoV (edit) |
Detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in sars patients by enzyme-linked immunosorbent assay. (edit) |
| SARSr-CoV (edit) |
Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. (edit) |
| SARSr-CoV (edit) |
Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species (edit) |
| SARSr-CoV (edit) |
Determination of SARS-coronavirus by a microfluidic chip system (edit) |
| SARSr-CoV (edit) |
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Development and evaluation of an efficient 3'-noncoding region based SARS coronavirus (SARS-CoV) RT-PCR assay for detection of SARS-CoV infections (edit) |
| SARSr-CoV (edit) |
Development and evaluation of an enzyme-linked immunosorbent assay for detection of antibodies against the spike protein of SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library (edit) |
| SARSr-CoV (edit) |
Development of Taqman RT-nested PCR system for clinical SARS-CoV detection. (edit) |
| SARSr-CoV (edit) |
Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant (edit) |
| SARSr-CoV (edit) |
Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus (edit) |
| SARSr-CoV (edit) |
Development of a dose-response model for SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Development of a method for concentrating and purifying SARS coronavirus RNA by a magnetic bead capture system. (edit) |
| SARSr-CoV (edit) |
Development of a molecular-beacon-based multi-allelic real-time RT-PCR assay for the detection of human coronavirus causing severe acute respiratory syndrome (SARS-CoV): a general methodology for detecting rapidly mutating viruses. (edit) |
| SARSr-CoV (edit) |
Development of a quantitative assay for SARS coronavirus and correlation of GAPDH mRNA with SARS coronavirus in clinical specimens (edit) |
| SARSr-CoV (edit) |
Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata (edit) |
| SARSr-CoV (edit) |
Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. (edit) |
| SARSr-CoV (edit) |
Development of a single nucleotide polymorphism DNA microarray for the detection and genotyping of the SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus (edit) |
| SARSr-CoV (edit) |
Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target (edit) |
| SARSr-CoV (edit) |
Development of human single-chain antibodies against SARS-associated coronavirus (edit) |
| SARSr-CoV (edit) |
Development of mouse hepatitis virus and SARS-CoV infectious cDNA constructs (edit) |
| SARSr-CoV (edit) |
Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies. (edit) |
| SARSr-CoV (edit) |
Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. (edit) |
| SARSr-CoV (edit) |
Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay (edit) |
| SARSr-CoV (edit) |
Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y. (edit) |
| SARSr-CoV (edit) |
Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava. (edit) |
| SARSr-CoV (edit) |
Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin (edit) |
| SARSr-CoV (edit) |
Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2. (edit) |
| SARSr-CoV (edit) |
Differential characteristics of the early stage of lung inflammation induced by SARS-CoV Nucleocapsid protein related to age in the mouse. (edit) |
| SARSr-CoV (edit) |
Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase (edit) |
| SARSr-CoV (edit) |
Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. (edit) |
| SARSr-CoV (edit) |
Differential stepwise evolution of SARS coronavirus functional proteins in different host species (edit) |
| SARSr-CoV (edit) |
Diffuse alveolar lesion in BALB/c mice induced with human reovirus BYD1 strain and its potential relation with SARS. (edit) |
| SARSr-CoV (edit) |
Direct sequencing of SARS-coronavirus S and N genes from clinical specimens shows limited variation. (edit) |
| SARSr-CoV (edit) |
Direct template matching reveals a host subcellular membrane gyroid cubic structure that is associated with SARS virus. (edit) |
| SARSr-CoV (edit) |
Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding (edit) |
| SARSr-CoV (edit) |
Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study (edit) |
| SARSr-CoV (edit) |
Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus [...] (edit) |
| SARSr-CoV (edit) |
Dissection of the fusion machine of SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus (edit) |
| SARSr-CoV (edit) |
Domestic poultry and SARS coronavirus, southern China (edit) |
| SARSr-CoV (edit) |
Double-antigen sandwich ELISA for detection of antibodies to SARS-associated coronavirus in human serum. (edit) |
| SARSr-CoV (edit) |
Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections (edit) |
| SARSr-CoV (edit) |
Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge (edit) |
| SARSr-CoV (edit) |
Dynamics of SARS-coronavirus HR2 domain in the prefusion and transition states (edit) |
| SARSr-CoV (edit) |
Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. (edit) |
| SARSr-CoV (edit) |
Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients (edit) |
| SARSr-CoV (edit) |
Early diagnosis of SARS coronavirus infection by real time RT-PCR. (edit) |
| SARSr-CoV (edit) |
Early events of SARS coronavirus infection in vero cells. (edit) |
| SARSr-CoV (edit) |
Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. (edit) |
| SARSr-CoV (edit) |
Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. (edit) |
| SARSr-CoV (edit) |
Effects of a SARS-associated coronavirus vaccine in monkeys. (edit) |
| SARSr-CoV (edit) |
Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine. (edit) |
| SARSr-CoV (edit) |
Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients (edit) |
| SARSr-CoV (edit) |
Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. (edit) |
| SARSr-CoV (edit) |
Efficacy of various disinfectants against SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Efficient and quick inactivation of SARS coronavirus and other microbes exposed to the surfaces of some metal catalysts. (edit) |
| SARSr-CoV (edit) |
Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. (edit) |
| SARSr-CoV (edit) |
Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a. (edit) |
| SARSr-CoV (edit) |
Elevated plasma surfactant protein D (SP-D) levels and a direct correlation with anti-severe acute respiratory syndrome coronavirus-specific IgG antibody in SARS patients. (edit) |
| SARSr-CoV (edit) |
Emergency medical services utilization during an outbreak of severe acute respiratory syndrome (SARS) and the incidence of SARS-associated coronavirus infection among emergency medical technicians. (edit) |
| SARSr-CoV (edit) |
Emodin inhibits current through SARS-associated coronavirus 3a protein (edit) |
| SARSr-CoV (edit) |
Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2. (edit) |
| SARSr-CoV (edit) |
Enhancement of SARS-CoV infection by proteases. (edit) |
| SARSr-CoV (edit) |
Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. (edit) |
| SARSr-CoV (edit) |
Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice (edit) |
| SARSr-CoV (edit) |
Environmental and occupational health response to SARS, Taiwan, 2003 (edit) |
| SARSr-CoV (edit) |
Environmental transmission of SARS at Amoy Gardens. (edit) |
| SARSr-CoV (edit) |
Erratum to: Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode. (edit) |
| SARSr-CoV (edit) |
Essential covalent linkage between the chymotrypsin-like domain and the extra domain of the SARS-CoV main protease. (edit) |
| SARSr-CoV (edit) |
Establishment and characterization of monoclonal antibodies against SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Establishment of a fluorescent polymerase chain reaction method for the detection of the SARS-associated coronavirus and its clinical application. (edit) |
| SARSr-CoV (edit) |
Establishment of the eukaryotic cell lines for inducible control of SARS-CoV nucleocapsid gene expression (edit) |
| SARSr-CoV (edit) |
Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery. (edit) |
| SARSr-CoV (edit) |
Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine. (edit) |
| SARSr-CoV (edit) |
Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Evaluation of a peptide-based enzyme immunoassay for anti-SARS coronavirus IgG antibody. (edit) |
| SARSr-CoV (edit) |
Evaluation of a real-time polymerase-chain reaction for severe acute respiratory syndrome (SARS) associated coronavirus in patients with hospitalised exacerbation of COPD. (edit) |
| SARSr-CoV (edit) |
Evaluation of a recombinant nucleocapsid protein-based assay for anti-SARS-CoV IgG detection. (edit) |
| SARSr-CoV (edit) |
Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. (edit) |
| SARSr-CoV (edit) |
Evaluation of homology modeling of the severe acute respiratory syndrome (SARS) coronavirus main protease for structure based drug design. (edit) |
| SARSr-CoV (edit) |
Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. (edit) |
| SARSr-CoV (edit) |
Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque. (edit) |
| SARSr-CoV (edit) |
Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice (edit) |
| SARSr-CoV (edit) |
Evidence for substrate binding-induced zwitterion formation in the catalytic Cys-His dyad of the SARS-CoV main protease (edit) |
| SARSr-CoV (edit) |
Evidence from the evolutionary analysis of nucleotide sequences for a recombinant history of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Evolution and variation of the SARS-CoV genome. (edit) |
| SARSr-CoV (edit) |
Evolutional insights on uncharacterized SARS coronavirus genes. (edit) |
| SARSr-CoV (edit) |
Excretion and detection of SARS coronavirus and its nucleic acid from digestive system (edit) |
| SARSr-CoV (edit) |
Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies (edit) |
| SARSr-CoV (edit) |
Experiences and implications of social workers practicing in a pediatric hospital environment affected by SARS. (edit) |
| SARSr-CoV (edit) |
Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design (edit) |
| SARSr-CoV (edit) |
Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). (edit) |
| SARSr-CoV (edit) |
Expression and characterization of recombinant S2 subunit of SARS-coronavirus S fusion protein. (edit) |
| SARSr-CoV (edit) |
Expression and functional characterisation of the putative SARS coronavirus non-structural proteins X1-X5. (edit) |
| SARSr-CoV (edit) |
Expression and purification of N and E proteins from severe acute respiratory syndrome (SARS)-associated coronavirus: a comparative study (edit) |
| SARSr-CoV (edit) |
Expression and purification of SARS coronavirus membrane protein. (edit) |
| SARSr-CoV (edit) |
Expression and purification of SARS coronavirus proteins using SUMO-fusions. (edit) |
| SARSr-CoV (edit) |
Expression and renaturation of a novel human single-chain Fv antibody against SARS-CoV (edit) |
| SARSr-CoV (edit) |
Expression cloning of functional receptor used by SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Expression of SARS-coronavirus envelope protein in Escherichia coli cells alters membrane permeability. (edit) |
| SARSr-CoV (edit) |
Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. (edit) |
| SARSr-CoV (edit) |
Expression of SARS-coronavirus spike glycoprotein in Pichia pastoris. (edit) |
| SARSr-CoV (edit) |
Expression of feline angiotensin converting enzyme 2 and its interaction with SARS-CoV S1 protein. (edit) |
| SARSr-CoV (edit) |
Expression, crystallization and preliminary crystallographic study of the C-terminal half of nsp2 from SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Expression, purification and crystallization of the SARS-CoV macro domain. (edit) |
| SARSr-CoV (edit) |
Expression, purification and sublocalization of SARS-CoV nucleocapsid protein in insect cells (edit) |
| SARSr-CoV (edit) |
Expression, purification, and characterization of SARS coronavirus RNA polymerase. (edit) |
| SARSr-CoV (edit) |
Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. (edit) |
| SARSr-CoV (edit) |
Ezrin interacts with the SARS coronavirus Spike protein and restrains infection at the entry stage (edit) |
| SARSr-CoV (edit) |
Factors associated with nosocomial SARS-CoV transmission among healthcare workers in Hanoi, Vietnam, 2003 (edit) |
| SARSr-CoV (edit) |
False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike p (edit) |
| SARSr-CoV (edit) |
False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based western blot assay were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Features discriminating SARS from other severe viral respiratory tract infections. (edit) |
| SARSr-CoV (edit) |
First external quality assurance of antibody diagnostic for SARS-new coronavirus. (edit) |
| SARSr-CoV (edit) |
Folding of the SARS coronavirus spike glycoprotein immunological fragment (SARS_S1b): thermodynamic and kinetic investigation correlating with three-dimensional structural modeling. (edit) |
| SARSr-CoV (edit) |
Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses. (edit) |
| SARSr-CoV (edit) |
From SARS coronavirus to novel animal and human coronaviruses. (edit) |
| SARSr-CoV (edit) |
From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses (edit) |
| SARSr-CoV (edit) |
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design (edit) |
| SARSr-CoV (edit) |
From genome to antivirals: SARS as a test tube. (edit) |
| SARSr-CoV (edit) |
From genome to drug lead: identification of a small-molecule inhibitor of the SARS virus. (edit) |
| SARSr-CoV (edit) |
Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. (edit) |
| SARSr-CoV (edit) |
Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. (edit) |
| SARSr-CoV (edit) |
Future antivirals-SMi conference: latest developments in HIV, hepatitis, herpes, influenza, RSV and SARS. (edit) |
| SARSr-CoV (edit) |
G0/G1 arrest and apoptosis induced by SARS-CoV 3b protein in transfected cells (edit) |
| SARSr-CoV (edit) |
Generating stable Chinese hamster ovary cell clones to produce a truncated SARS-CoV spike protein for vaccine development. (edit) |
| SARSr-CoV (edit) |
Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach (edit) |
| SARSr-CoV (edit) |
Generation of predictive pharmacophore model for SARS-coronavirus main proteinase (edit) |
| SARSr-CoV (edit) |
Genetic variation of SARS coronavirus in Beijing Hospital (edit) |
| SARSr-CoV (edit) |
Genetic variation of the human α-2-Heremans-Schmid glycoprotein (AHSG) gene associated with the risk of SARS-CoV infection (edit) |
| SARSr-CoV (edit) |
Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross (edit) |
| SARSr-CoV (edit) |
Genome organization of the SARS-CoV (edit) |
| SARSr-CoV (edit) |
Genomic analysis and geographic visualization of H5N1 and SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Genomic classification using an information-based similarity index: application to the SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Genosensor on gold films with enzymatic electrochemical detection of a SARS virus sequence. (edit) |
| SARSr-CoV (edit) |
Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa. (edit) |
| SARSr-CoV (edit) |
Getting ready for SARS. Officials consider tough measures to contain outbreaks should deadly virus return. (edit) |
| SARSr-CoV (edit) |
Global virus alert. How SARS highlighted the risk of viral pandemics (edit) |
| SARSr-CoV (edit) |
Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
Growth kinetics of SARS-coronavirus in Vero E6 cells. (edit) |
| SARSr-CoV (edit) |
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins (edit) |
| SARSr-CoV (edit) |
Heat sensitivity of a SARS-associated coronavirus introduced into plasma products. (edit) |
| SARSr-CoV (edit) |
Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Heterologous expression of SARS-CoV ORF10 and X5 genes in E. coli and Streptomyces lividans TK24. (edit) |
| SARSr-CoV (edit) |
Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS. (edit) |
| SARSr-CoV (edit) |
High expression level of soluble SARS spike protein mediated by adenovirus in HEK293 cells (edit) |
| SARSr-CoV (edit) |
High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells (edit) |
| SARSr-CoV (edit) |
High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery (edit) |
| SARSr-CoV (edit) |
High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. (edit) |
| SARSr-CoV (edit) |
High-yield expression of recombinant SARS coronavirus nucleocapsid protein in methylotrophic yeast Pichia pastoris (edit) |
| SARSr-CoV (edit) |
Highly attenuated vaccinia virus DIs as a potential SARS vaccine. (edit) |
| SARSr-CoV (edit) |
Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression (edit) |
| SARSr-CoV (edit) |
Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. (edit) |
| SARSr-CoV (edit) |
Hong Kong health chief falls ill with suspected SARS virus. (edit) |
| SARSr-CoV (edit) |
How China’s ‘Bat Woman’ Hunted Down Viruses from SARS to the New Coronavirus (edit) |
| SARSr-CoV (edit) |
How change of public transportation usage reveals fear of the SARS virus in a city (edit) |
| SARSr-CoV (edit) |
How the SARS coronavirus causes disease: host or organism? (edit) |
| SARSr-CoV (edit) |
Human CD4(+) memory T-lymphocyte responses to SARS coronavirus infection (edit) |
| SARSr-CoV (edit) |
Human LINE1 endonuclease domain as a putative target of SARS-associated autoantibodies involved in the pathogenesis of severe acute respiratory syndrome (edit) |
| SARSr-CoV (edit) |
Human SARS-coronavirus RNA-dependent RNA polymerase: activity determinants and nucleoside analogue inhibitors. (edit) |
| SARSr-CoV (edit) |
Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines (edit) |
| SARSr-CoV (edit) |
Human memory T cell responses to SARS-CoV E protein. (edit) |
| SARSr-CoV (edit) |
Human metapneumovirus pneumonia in an adult patient hospitalized for suspected severe acute respiratory syndrome (SARS) (edit) |
| SARSr-CoV (edit) |
Human metapneumovirus-associated atypical pneumonia and SARS. (edit) |
| SARSr-CoV (edit) |
Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing (edit) |
| SARSr-CoV (edit) |
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. (edit) |
| SARSr-CoV (edit) |
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants (edit) |
| SARSr-CoV (edit) |
Human severe acute respiratory syndrome (SARS) and feline coronaviroses. (edit) |
| SARSr-CoV (edit) |
Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice (edit) |
| SARSr-CoV (edit) |
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. (edit) |
| SARSr-CoV (edit) |
Identification and characterization of three novel small interference RNAs that effectively down-regulate the isolated nucleocapsid gene expression of SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Identification and molecular cloning and sequence analysis of a novel coronavirus from patients with SARS by RT-PCR (edit) |
| SARSr-CoV (edit) |
Identification of SARS-like coronaviruses in horseshoe bats (Rhinolophus hipposideros) in Slovenia (edit) |
| SARSr-CoV (edit) |
Identification of a B-cell antigenic epitope at the N-terminus of SARS-CoV M protein and characterization of monoclonal antibody against the protein. (edit) |
| SARSr-CoV (edit) |
Identification of a Novel Small Molecule Inhibitor Against SARS Coronavirus Helicase (edit) |
| SARSr-CoV (edit) |
Identification of a new region of SARS-CoV S protein critical for viral entry (edit) |
| SARSr-CoV (edit) |
Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Identification of a novel transcriptional repressor (HEPIS) that interacts with nsp-10 of SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein (edit) |
| SARSr-CoV (edit) |
Identification of an epitope of SARS-coronavirus nucleocapsid protein. (edit) |
| SARSr-CoV (edit) |
Identification of effective siRNA blocking the expression of SARS viral envelope E and RDRP genes. (edit) |
| SARSr-CoV (edit) |
Identification of essential genes as a strategy to select a SARS candidate vaccine using a SARS-CoV infectious cDNA. (edit) |
| SARSr-CoV (edit) |
Identification of ferret ACE2 and its receptor function for SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Identification of human cell line model of persistent SARS coronavirus infection and studies of the response to cytokines and chemokines. (edit) |
| SARSr-CoV (edit) |
Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. (edit) |
| SARSr-CoV (edit) |
Identification of immunogenic determinants of the spike protein of SARS-like coronavirus (edit) |
| SARSr-CoV (edit) |
Identification of mimotope peptides which bind to the SARS-CoV spike protein specific monoclonal antibody 2C5 with phage-displayed peptides library (edit) |
| SARSr-CoV (edit) |
Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein (edit) |
| SARSr-CoV (edit) |
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. (edit) |
| SARSr-CoV (edit) |
Identification of natural compounds with antiviral activities against SARS-associated coronavirus (edit) |
| SARSr-CoV (edit) |
Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings (edit) |
| SARSr-CoV (edit) |
Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. (edit) |
| SARSr-CoV (edit) |
Identification of probable genomic packaging signal sequence from SARS-CoV genome by bioinformatics analysis (edit) |
| SARSr-CoV (edit) |
Identification of pulmonary Oct-4+ stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV) infection in vitro (edit) |
| SARSr-CoV (edit) |
Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library (edit) |
| SARSr-CoV (edit) |
Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine. (edit) |
| SARSr-CoV (edit) |
Identification of two antigenic epitopes on SARS-CoV spike protein. (edit) |
| SARSr-CoV (edit) |
Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. (edit) |
| SARSr-CoV (edit) |
Identifying a killer: SARS virus. (edit) |
| SARSr-CoV (edit) |
Identifying inhibitors of the SARS coronavirus proteinase. (edit) |
| SARSr-CoV (edit) |
Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine (edit) |
| SARSr-CoV (edit) |
Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain. (edit) |
| SARSr-CoV (edit) |
Immune responses to T-cell epitopes of SARS CoV-N protein are enhanced by N immunization with a chimera of lysosome-associated membrane protein. (edit) |
| SARSr-CoV (edit) |
Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus (edit) |
| SARSr-CoV (edit) |
Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses. (edit) |
| SARSr-CoV (edit) |
Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates (edit) |
| SARSr-CoV (edit) |
Immunofluorescence assay for detection of the nucleocapsid antigen of the severe acute respiratory syndrome (SARS)-associated coronavirus in cells derived from throat wash samples of patients with SARS. (edit) |
| SARSr-CoV (edit) |
Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates (edit) |
| SARSr-CoV (edit) |
Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine (edit) |
| SARSr-CoV (edit) |
Immunogenicity difference between the SARS coronavirus and the bat SARS-like coronavirus spike (S) proteins. (edit) |
| SARSr-CoV (edit) |
Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine (edit) |
| SARSr-CoV (edit) |
Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. (edit) |
| SARSr-CoV (edit) |
Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan (edit) |
| SARSr-CoV (edit) |
Immunological responses against SARS-coronavirus infection in humans. (edit) |
| SARSr-CoV (edit) |
Immunological, structural, and preliminary X-ray diffraction characterizations of the fusion core of the SARS-coronavirus spike protein. (edit) |
| SARSr-CoV (edit) |
Immunopathogenesis of coronavirus infections: implications for SARS. (edit) |
| SARSr-CoV (edit) |
Importance of Akt signaling pathway for apoptosis in SARS-CoV-infected Vero E6 cells. (edit) |
| SARSr-CoV (edit) |
Importance of SARS-CoV spike protein Trp-rich region in viral infectivity. (edit) |
| SARSr-CoV (edit) |
Improved prediction of MHC class I binders/non-binders peptides through artificial neural network using variable learning rate: SARS corona virus, a case study. (edit) |
| SARSr-CoV (edit) |
In Vitro Antiviral Activity of some Novel Isatin Derivatives against HCV and SARS-CoV Viruses (edit) |
| SARSr-CoV (edit) |
In silico prediction of SARS protease inhibitors by virtual high throughput screening. (edit) |
| SARSr-CoV (edit) |
In vitro anti-hepatitis B and SARS virus activities of a titanium-substituted-heteropolytungstate. (edit) |
| SARSr-CoV (edit) |
In vitro biochemical and thermodynamic characterization of nucleocapsid protein of SARS. (edit) |
| SARSr-CoV (edit) |
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. (edit) |
| SARSr-CoV (edit) |
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. (edit) |
| SARSr-CoV (edit) |
Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. (edit) |
| SARSr-CoV (edit) |
Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. (edit) |
| SARSr-CoV (edit) |
Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions, and chemical reagents. (edit) |
| SARSr-CoV (edit) |
Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Increase of SARS-CoV 3CL peptidase activity due to macromolecular crowding effects in the milieu composition. (edit) |
| SARSr-CoV (edit) |
Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. (edit) |
| SARSr-CoV (edit) |
Indomethacin has a potent antiviral activity against SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. (edit) |
| SARSr-CoV (edit) |
Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice. (edit) |
| SARSr-CoV (edit) |
Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. (edit) |
| SARSr-CoV (edit) |
Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. (edit) |
| SARSr-CoV (edit) |
Infection of human airway epithelia by SARS coronavirus is associated with ACE2 expression and localization (edit) |
| SARSr-CoV (edit) |
Infectious diseases. One year after outbreak, SARS virus yields some secrets. (edit) |
| SARSr-CoV (edit) |
Influence of HLA gene polymorphisms on susceptibility and outcome post infection with the SARS-CoV virus. (edit) |
| SARSr-CoV (edit) |
Influence of hydrophobic and electrostatic residues on SARS-coronavirus S2 protein stability: insights into mechanisms of general viral fusion and inhibitor design (edit) |
| SARSr-CoV (edit) |
Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development. (edit) |
| SARSr-CoV (edit) |
Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts (edit) |
| SARSr-CoV (edit) |
Influenza and SARS: the impact of viral pandemics on maritime health. (edit) |
| SARSr-CoV (edit) |
Influenza as a model system for studying the cross-species transfer and evolution of the SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Inhibition of SARS coronavirus helicase by bismuth complexes. (edit) |
| SARSr-CoV (edit) |
Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs (edit) |
| SARSr-CoV (edit) |
Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans (edit) |
| SARSr-CoV (edit) |
Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3) (edit) |
| SARSr-CoV (edit) |
Inhibition of SARS-CoV gene expression by adenovirus-delivered small hairpin RNA. (edit) |
| SARSr-CoV (edit) |
Inhibition of SARS-CoV replication by siRNA. (edit) |
| SARSr-CoV (edit) |
Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. (edit) |
| SARSr-CoV (edit) |
Inhibition of SARS-associated coronavirus infection and replication by RNA interference. (edit) |
| SARSr-CoV (edit) |
Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. (edit) |
| SARSr-CoV (edit) |
Inhibition of cell proliferation by SARS-CoV infection in Vero E6 cells. (edit) |
| SARSr-CoV (edit) |
Inhibition of cytokine gene expression and induction of chemokine genes in non-lymphatic cells infected with SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics (edit) |
| SARSr-CoV (edit) |
Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs. (edit) |
| SARSr-CoV (edit) |
Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin (edit) |
| SARSr-CoV (edit) |
Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein (edit) |
| SARSr-CoV (edit) |
Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. (edit) |
| SARSr-CoV (edit) |
Inhibitor design for SARS coronavirus main protease based on "distorted key theory". (edit) |
| SARSr-CoV (edit) |
Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV (edit) |
| SARSr-CoV (edit) |
Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies (edit) |
| SARSr-CoV (edit) |
Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay (edit) |
| SARSr-CoV (edit) |
Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
Initial viral load and the outcomes of SARS. (edit) |
| SARSr-CoV (edit) |
Insights from the association of SARS-CoV S-protein with its receptor, ACE2. (edit) |
| SARSr-CoV (edit) |
Insurance and epidemics: SARS, West Nile virus and Nipah virus. (edit) |
| SARSr-CoV (edit) |
Interaction between SARS-CoV helicase and a multifunctional cellular protein (Ddx5) revealed by yeast and mammalian cell two-hybrid systems (edit) |
| SARSr-CoV (edit) |
Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. (edit) |
| SARSr-CoV (edit) |
Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. (edit) |
| SARSr-CoV (edit) |
Interaction of a peptide corresponding to the loop domain of the S2 SARS-CoV virus protein with model membranes. (edit) |
| SARSr-CoV (edit) |
Interactions among SARS-CoV accessory proteins revealed by bimolecular fluorescence complementation assay. (edit) |
| SARSr-CoV (edit) |
Interactions between SARS coronavirus and its receptor (edit) |
| SARSr-CoV (edit) |
Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells (edit) |
| SARSr-CoV (edit) |
Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models. (edit) |
| SARSr-CoV (edit) |
Interferon and cytokine responses to SARS-coronavirus infection (edit) |
| SARSr-CoV (edit) |
Interferon interplay helps tissue cells to cope with SARS-coronavirus infection (edit) |
| SARSr-CoV (edit) |
Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation (edit) |
| SARSr-CoV (edit) |
Interferon-beta 1a and SARS coronavirus replication (edit) |
| SARSr-CoV (edit) |
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). (edit) |
| SARSr-CoV (edit) |
Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. (edit) |
| SARSr-CoV (edit) |
International research networks in viral structural proteomics: again, lessons from SARS. (edit) |
| SARSr-CoV (edit) |
Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. (edit) |
| SARSr-CoV (edit) |
Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. (edit) |
| SARSr-CoV (edit) |
Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against (edit) |
| SARSr-CoV (edit) |
Intraspecies diversity of SARS-like coronaviruses in Rhinolophus sinicus and its implications for the origin of SARS coronaviruses in humans. (edit) |
| SARSr-CoV (edit) |
Investigation of immunogenic T-cell epitopes in SARS virus nucleocapsid protein and their role in the prevention and treatment of SARS infection. (edit) |
| SARSr-CoV (edit) |
Investigation of interaction between two neutralizing monoclonal antibodies and SARS virus using biosensor based on imaging ellipsometry. (edit) |
| SARSr-CoV (edit) |
Investigation of interactions between two monoclonal antibodies and SARS virus with a Label-free Protein Array. (edit) |
| SARSr-CoV (edit) |
Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives. (edit) |
| SARSr-CoV (edit) |
Is serum in childhood naturally protective against SARS-coronavirus? (edit) |
| SARSr-CoV (edit) |
Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections? Lack of efficacy of promazine on SARS-CoV replication in a mouse model (edit) |
| SARSr-CoV (edit) |
Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? (edit) |
| SARSr-CoV (edit) |
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor (edit) |
| SARSr-CoV (edit) |
Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China (edit) |
| SARSr-CoV (edit) |
Isolation and identification of an scFv antibody against nucleocapsid protein of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. (edit) |
| SARSr-CoV (edit) |
Isolation of virus from a SARS patient and genome-wide analysis of genetic mutations related to pathogenesis and epidemiology from 47 SARS-CoV isolates (edit) |
| SARSr-CoV (edit) |
JNK and PI3k/Akt signaling pathways are required for establishing persistent SARS-CoV infection in Vero E6 cells. (edit) |
| SARSr-CoV (edit) |
Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARS (edit) |
| SARSr-CoV (edit) |
Label-free, electrical detection of the SARS virus N-protein with nanowire biosensors utilizing antibody mimics as capture probes (edit) |
| SARSr-CoV (edit) |
Laboratory containment of SARS virus. (edit) |
| SARSr-CoV (edit) |
Lack of association between HLA-A, -B and -DRB1 alleles and the development of SARS: a cohort of 95 SARS-recovered individuals in a population of Guangdong, southern China. (edit) |
| SARSr-CoV (edit) |
Lack of association between polymorphisms of MASP2 and susceptibility to SARS coronavirus infection (edit) |
| SARSr-CoV (edit) |
Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model (edit) |
| SARSr-CoV (edit) |
Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen (edit) |
| SARSr-CoV (edit) |
Lessons learned from SARS outbreak prompt rapid response to new coronavirus. (edit) |
| SARSr-CoV (edit) |
Lipid rafts are involved in SARS-CoV entry into Vero E6 cells (edit) |
| SARSr-CoV (edit) |
Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. (edit) |
| SARSr-CoV (edit) |
Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. (edit) |
| SARSr-CoV (edit) |
Long-term SARS coronavirus excretion from patient cohort, China (edit) |
| SARSr-CoV (edit) |
Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine (edit) |
| SARSr-CoV (edit) |
Longitudinal analysis of Severe Acute Respiratory Syndrome (SARS) coronavirus-specific antibody in SARS patients (edit) |
| SARSr-CoV (edit) |
Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. (edit) |
| SARSr-CoV (edit) |
Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Longitudinal surveillance of SARS-like coronaviruses in bats by quantitative real-time PCR. (edit) |
| SARSr-CoV (edit) |
Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes (edit) |
| SARSr-CoV (edit) |
MERS, SARS and other coronaviruses as causes of pneumonia. (edit) |
| SARSr-CoV (edit) |
Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses (edit) |
| SARSr-CoV (edit) |
Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. (edit) |
| SARSr-CoV (edit) |
Mass spectrometric characterization of proteins from the SARS virus: a preliminary report (edit) |
| SARSr-CoV (edit) |
Mechanism for controlling the monomer-dimer conversion of SARS coronavirus main protease (edit) |
| SARSr-CoV (edit) |
Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. (edit) |
| SARSr-CoV (edit) |
Medical treatment of viral pneumonia including SARS in immunocompetent adult (edit) |
| SARSr-CoV (edit) |
Medusa's ugly head again: from SARS to MERS-CoV. (edit) |
| SARSr-CoV (edit) |
Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection (edit) |
| SARSr-CoV (edit) |
Mice susceptible to SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. (edit) |
| SARSr-CoV (edit) |
Microarray and real-time RT-PCR analyses of differential human gene expression patterns induced by severe acute respiratory syndrome (SARS) coronavirus infection of Vero cells. (edit) |
| SARSr-CoV (edit) |
Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease (edit) |
| SARSr-CoV (edit) |
Middle East respiratory syndrome: SARS redux? (edit) |
| SARSr-CoV (edit) |
Mining SARS-CoV protease cleavage data using non-orthogonal decision trees: a novel method for decisive template selection (edit) |
| SARSr-CoV (edit) |
Moderate mutation rate in the SARS coronavirus genome and its implications (edit) |
| SARSr-CoV (edit) |
Modification of SARS-CoV S1 gene render expression in Pichia pastoris. (edit) |
| SARSr-CoV (edit) |
Molecular advances in severe acute respiratory syndrome-associated coronavirus (SARS-CoV). (edit) |
| SARSr-CoV (edit) |
Molecular advances in the cell biology of SARS-CoV and current disease prevention strategies (edit) |
| SARSr-CoV (edit) |
Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Molecular cloning, expression, and purification of SARS-CoV nsp13. (edit) |
| SARSr-CoV (edit) |
Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro. (edit) |
| SARSr-CoV (edit) |
Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors. (edit) |
| SARSr-CoV (edit) |
Molecular epidemiology of SARS-associated coronavirus, Beijing (edit) |
| SARSr-CoV (edit) |
Molecular evolution and multilocus sequence typing of 145 strains of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. (edit) |
| SARSr-CoV (edit) |
Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. (edit) |
| SARSr-CoV (edit) |
Molecular signature of clinical severity in recovering patients with severe acute respiratory syndrome coronavirus (SARS-CoV). (edit) |
| SARSr-CoV (edit) |
Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV). (edit) |
| SARSr-CoV (edit) |
Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins (edit) |
| SARSr-CoV (edit) |
Morphology and morphogenesis of severe acute respiratory syndrome (SARS)-associated virus. (edit) |
| SARSr-CoV (edit) |
Mouse studies of SARS coronavirus-specific immune responses to recombinant replication-defective adenovirus expressing SARS coronavirus N protein. (edit) |
| SARSr-CoV (edit) |
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. (edit) |
| SARSr-CoV (edit) |
Multi-organ lesions in suckling mice infected with SARS-associated mammalian reovirus linked with apoptosis induced by viral proteins μ1 and σ1 (edit) |
| SARSr-CoV (edit) |
Multi-zone modeling of probable SARS virus transmission by airflow between flats in Block E, Amoy Gardens. (edit) |
| SARSr-CoV (edit) |
Murine hepatitis virus strain 1 as a model for severe acute respiratory distress syndrome (SARS). (edit) |
| SARSr-CoV (edit) |
Mustela vison ACE2 functions as a receptor for SARS-coronavirus (edit) |
| SARSr-CoV (edit) |
Mutagenesis of the transmembrane domain of the SARS coronavirus spike glycoprotein: refinement of the requirements for SARS coronavirus cell entry (edit) |
| SARSr-CoV (edit) |
Mutation analysis of 20 SARS virus genome sequences: evidence for negative selection in replicase ORF1b and spike gene (edit) |
| SARSr-CoV (edit) |
Mutational and inhibitive analysis of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer-based assays. (edit) |
| SARSr-CoV (edit) |
Mutational dynamics of the SARS coronavirus in cell culture and human populations isolated in 2003 (edit) |
| SARSr-CoV (edit) |
Mutational patterns correlate with genome organization in SARS and other coronaviruses (edit) |
| SARSr-CoV (edit) |
MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. (edit) |
| SARSr-CoV (edit) |
NMR assignment of the protein nsp3a from SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model. (edit) |
| SARSr-CoV (edit) |
Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein (edit) |
| SARSr-CoV (edit) |
Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology (edit) |
| SARSr-CoV (edit) |
New Frameshifting Pseudoknot Found in SARS Virus (edit) |
| SARSr-CoV (edit) |
New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives. (edit) |
| SARSr-CoV (edit) |
New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus (edit) |
| SARSr-CoV (edit) |
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors (edit) |
| SARSr-CoV (edit) |
Novel Alphacoronaviruses and Paramyxoviruses Cocirculate with Type 1 and Severe Acute Respiratory System (SARS)-Related Betacoronaviruses in Synanthropic Bats of Luxembourg (edit) |
| SARSr-CoV (edit) |
Novel SARS-like betacoronaviruses in bats, China, 2011. (edit) |
| SARSr-CoV (edit) |
Novel rapid immunochromatographic test based on an enzyme immunoassay for detecting nucleocapsid antigen in SARS-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
Novel system for detecting SARS coronavirus nucleocapsid protein using an ssDNA aptamer (edit) |
| SARSr-CoV (edit) |
Object-oriented biological system integration: a SARS coronavirus example. (edit) |
| SARSr-CoV (edit) |
Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. (edit) |
| SARSr-CoV (edit) |
One-tube nested RT-PCR enabled by using a plastic film and its application for the rapid detection of SARS-virus. (edit) |
| SARSr-CoV (edit) |
Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate (edit) |
| SARSr-CoV (edit) |
Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. (edit) |
| SARSr-CoV (edit) |
Osteonecrosis in patients after severe acute respiratory syndrome (SARS): possible role of anticardiolipin antibodies. (edit) |
| SARSr-CoV (edit) |
PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Palindromes in SARS and Other Coronaviruses (edit) |
| SARSr-CoV (edit) |
Palmitoylation of SARS-CoV S protein is necessary for partitioning into detergent-resistant membranes and cell-cell fusion but not interaction with M protein (edit) |
| SARSr-CoV (edit) |
Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated cell fusion. (edit) |
| SARSr-CoV (edit) |
Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. (edit) |
| SARSr-CoV (edit) |
Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Pathogenesis of SARS coronavirus infection using human lung epithelial cells: an in vitro model. (edit) |
| SARSr-CoV (edit) |
Pathological Clues to How the SARS Virus Kills (edit) |
| SARSr-CoV (edit) |
Pathology of experimental SARS coronavirus infection in cats and ferrets. (edit) |
| SARSr-CoV (edit) |
Pathology of guinea pigs experimentally infected with a novel reovirus and coronavirus isolated from SARS patients (edit) |
| SARSr-CoV (edit) |
Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. (edit) |
| SARSr-CoV (edit) |
Peptide domain involved in the interaction between membrane protein and nucleocapsid protein of SARS-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
Peptide mimicrying between SARS coronavirus spike protein and human proteins reacts with SARS patient serum (edit) |
| SARSr-CoV (edit) |
Peptides derived from HIV-1, HIV-2, Ebola virus, SARS coronavirus and coronavirus 229E exhibit high affinity binding to the formyl peptide receptor (edit) |
| SARSr-CoV (edit) |
Peptides from the SARS-associated coronavirus as tags for protein expression and purification. (edit) |
| SARSr-CoV (edit) |
Persistent infection of SARS coronavirus in colonic cells in vitro. (edit) |
| SARSr-CoV (edit) |
Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen (edit) |
| SARSr-CoV (edit) |
Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. (edit) |
| SARSr-CoV (edit) |
Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cells (edit) |
| SARSr-CoV (edit) |
Phylogenetic analysis and sequence comparisons of structural and non-structural SARS coronavirus proteins in Taiwan. (edit) |
| SARSr-CoV (edit) |
Phylogenetic analysis of the full-length SARS-CoV sequences: evidence for phylogenetic discordance in three genomic regions. (edit) |
| SARSr-CoV (edit) |
Phylogenetic perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses (edit) |
| SARSr-CoV (edit) |
Phylogenomics and bioinformatics of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Phylogeny of the SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. (edit) |
| SARSr-CoV (edit) |
Piezoelectric immunosensor for SARS-associated coronavirus in sputum. (edit) |
| SARSr-CoV (edit) |
Polymorphism of SARS-CoV genomes. (edit) |
| SARSr-CoV (edit) |
Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide. (edit) |
| SARSr-CoV (edit) |
Possible SARS coronavirus transmission during cardiopulmonary resuscitation (edit) |
| SARSr-CoV (edit) |
Possible central nervous system infection by SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients (edit) |
| SARSr-CoV (edit) |
Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid (edit) |
| SARSr-CoV (edit) |
Potent and specific inhibition of SARS-CoV antigen expression by RNA interference (edit) |
| SARSr-CoV (edit) |
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies (edit) |
| SARSr-CoV (edit) |
Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus (edit) |
| SARSr-CoV (edit) |
Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma). (edit) |
| SARSr-CoV (edit) |
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association (edit) |
| SARSr-CoV (edit) |
Potential antivirals and antiviral strategies against SARS coronavirus infections (edit) |
| SARSr-CoV (edit) |
Potential cross-reactivity of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid (N)-based IgG ELISA assay for plasma samples from HIV-1 positive intravenous drug users (IDUs). (edit) |
| SARSr-CoV (edit) |
Potential for receptor-based antiviral drugs against SARS. (edit) |
| SARSr-CoV (edit) |
Potential targets for anti-SARS drugs in the structural proteins from SARS related coronavirus. (edit) |
| SARSr-CoV (edit) |
Prediction of amino acid pairs sensitive to mutations in the spike protein from SARS related coronavirus. (edit) |
| SARSr-CoV (edit) |
Prediction of functional class of the SARS coronavirus proteins by a statistical learning method. (edit) |
| SARSr-CoV (edit) |
Prediction of proteinase cleavage sites in polyproteins of coronaviruses and its applications in analyzing SARS-CoV genomes. (edit) |
| SARSr-CoV (edit) |
Prediction of quaternary assembly of SARS coronavirus peplomer. (edit) |
| SARSr-CoV (edit) |
Preliminary study on the detection of the SARS-CoV specific target cDNA fragments by multiplex PCR. (edit) |
| SARSr-CoV (edit) |
Preparation and characterization of monoclonal antibodies against S1 domain at N-terminal residues 249 to 667 of SARS-associated coronavirus S1 protein. (edit) |
| SARSr-CoV (edit) |
Preparation and evaluation of anti-SARS coronavirus IgY from yolks of immunized SPF chickens (edit) |
| SARSr-CoV (edit) |
Prevalence of IgG antibody to SARS-associated coronavirus in animal traders--Guangdong Province, China, 2003. (edit) |
| SARSr-CoV (edit) |
Prevalence of SARS-CoV antibody in all Hong Kong patient contacts. (edit) |
| SARSr-CoV (edit) |
Prevalence of non-pneumonic infections with SARS-correlated virus. (edit) |
| SARSr-CoV (edit) |
Prevalence of non-pneumonic infections with SARS-correlated virus. (edit) |
| SARSr-CoV (edit) |
Prevalence of subclinical infection by the SARS coronavirus among general practitioners in Hong Kong. (edit) |
| SARSr-CoV (edit) |
Primary characterization of SARS coronavirus strain Frankfurt 1. (edit) |
| SARSr-CoV (edit) |
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. (edit) |
| SARSr-CoV (edit) |
Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Probing the structure of the SARS coronavirus using scanning electron microscopy (edit) |
| SARSr-CoV (edit) |
Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection. (edit) |
| SARSr-CoV (edit) |
Production of a monoclonal antibody against SARS-CoV spike protein with single intrasplenic immunization of plasmid DNA. (edit) |
| SARSr-CoV (edit) |
Production of an anti-severe acute respiratory syndrome (SARS) coronavirus human monoclonal antibody Fab fragment by using a combinatorial immunoglobulin gene library derived from patients who recovered from SARS. (edit) |
| SARSr-CoV (edit) |
Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43. (edit) |
| SARSr-CoV (edit) |
Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients. (edit) |
| SARSr-CoV (edit) |
Profile of specific antibodies to the SARS-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients. (edit) |
| SARSr-CoV (edit) |
Programmed ribosomal frameshifting in HIV-1 and the SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Programmed ribosomal frameshifting in decoding the SARS-CoV genome (edit) |
| SARSr-CoV (edit) |
Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy. (edit) |
| SARSr-CoV (edit) |
Prokaryotic expression of S2 extracellular domain of SARS coronavirus spike protein and its fusion with Hela cell membrane (edit) |
| SARSr-CoV (edit) |
Prokaryotic expression, refolding, and purification of fragment 450-650 of the spike protein of SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids (edit) |
| SARSr-CoV (edit) |
Promoter activity of SARS coronavirus 5' UTR sequence in eukaryotic cells. (edit) |
| SARSr-CoV (edit) |
Properties of isonucleotide-incorporated oligodeoxynucleotides and inhibition of the expression of spike protein of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus (edit) |
| SARSr-CoV (edit) |
Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model (edit) |
| SARSr-CoV (edit) |
Proposal for vaccination against SARS coronavirus using avian infectious bronchitis virus strain H from The Netherlands. (edit) |
| SARSr-CoV (edit) |
Protein transfer enhances cellular immune responses to DNA vaccination against SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Proteomic analysis of SARS associated coronavirus using two-dimensional liquid chromatography mass spectrometry and one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by mass spectroemtric analysis. (edit) |
| SARSr-CoV (edit) |
Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins. (edit) |
| SARSr-CoV (edit) |
Pseudotyped vesicular stomatitis virus for functional analysis of SARS coronavirus spike protein (edit) |
| SARSr-CoV (edit) |
Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). (edit) |
| SARSr-CoV (edit) |
Putative hAPN receptor binding sites in SARS_CoV spike protein. (edit) |
| SARSr-CoV (edit) |
Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture. (edit) |
| SARSr-CoV (edit) |
Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. (edit) |
| SARSr-CoV (edit) |
Quantitative analysis of severe acute respiratory syndrome (SARS)-associated coronavirus-infected cells using proteomic approaches: implications for cellular responses to virus infection. (edit) |
| SARSr-CoV (edit) |
Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassay (edit) |
| SARSr-CoV (edit) |
Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: implications for the functional roles of S2 subunit (edit) |
| SARSr-CoV (edit) |
Quantitative evaluation of infection control models in the prevention of nosocomial transmission of SARS virus to healthcare workers: implication to nosocomial viral infection control for healthcare workers (edit) |
| SARSr-CoV (edit) |
Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in post-mortem tissues. (edit) |
| SARSr-CoV (edit) |
Questions about comparative genomics of SARS coronavirus isolates. (edit) |
| SARSr-CoV (edit) |
RNA aptamer-based sensitive detection of SARS coronavirus nucleocapsid protein. (edit) |
| SARSr-CoV (edit) |
RNA dimerization plays a role in ribosomal frameshifting of the SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Rapid and sensitive detection of multiple genes from the SARS-coronavirus using quantitative RT-PCR with dual systems. (edit) |
| SARSr-CoV (edit) |
Rapid detection of the severe acute respiratory syndrome (SARS) coronavirus by a loop-mediated isothermal amplification assay. (edit) |
| SARSr-CoV (edit) |
Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS). (edit) |
| SARSr-CoV (edit) |
Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (edit) |
| SARSr-CoV (edit) |
Real-time NASBA detection of SARS-associated coronavirus and comparison with real-time reverse transcription-PCR (edit) |
| SARSr-CoV (edit) |
Real-time polymerase chain reaction for detecting SARS coronavirus, Beijing, 2003 (edit) |
| SARSr-CoV (edit) |
Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus (edit) |
| SARSr-CoV (edit) |
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. (edit) |
| SARSr-CoV (edit) |
Receptor recognition and cross-species infections of SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine (edit) |
| SARSr-CoV (edit) |
Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines (edit) |
| SARSr-CoV (edit) |
Recombinant protein-based enzyme-linked immunosorbent assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in SARS patients. (edit) |
| SARSr-CoV (edit) |
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity (edit) |
| SARSr-CoV (edit) |
Reconstitution of the receptor-binding motif of the SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Recurrent mutations associated with isolation and passage of SARS coronavirus in cells from non-human primates (edit) |
| SARSr-CoV (edit) |
Reduced incorporation of SARS-CoV spike protein into viral particles due to amino acid substitutions within the receptor binding domain. (edit) |
| SARSr-CoV (edit) |
Reference gene selection for quantitative real-time PCR analysis in virus infected cells: SARS corona virus, Yellow fever virus, Human Herpesvirus-6, Camelpox virus and Cytomegalovirus infections (edit) |
| SARSr-CoV (edit) |
Regulation of p90RSK phosphorylation by SARS-CoV infection in Vero E6 cells. (edit) |
| SARSr-CoV (edit) |
Relationship of SARS-CoV to other pathogenic RNA viruses explored by tetranucleotide usage profiling (edit) |
| SARSr-CoV (edit) |
Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. (edit) |
| SARSr-CoV (edit) |
Reliability of detecting SARS-CoV antibody for diagnosis of SARS (edit) |
| SARSr-CoV (edit) |
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. (edit) |
| SARSr-CoV (edit) |
Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. (edit) |
| SARSr-CoV (edit) |
Residue analysis of a CTL epitope of SARS-CoV spike protein by IFN-gamma production and bioinformatics prediction (edit) |
| SARSr-CoV (edit) |
Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. (edit) |
| SARSr-CoV (edit) |
Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination (edit) |
| SARSr-CoV (edit) |
Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. (edit) |
| SARSr-CoV (edit) |
Ribavirin for SARS in children. (edit) |
| SARSr-CoV (edit) |
Ribavirin in the treatment of SARS: A new trick for an old drug? (edit) |
| SARSr-CoV (edit) |
Ribavirin in the treatment of severe acute respiratory syndrome (SARS). (edit) |
| SARSr-CoV (edit) |
Risks to healthcare workers with emerging diseases: lessons from MERS-CoV, Ebola, SARS, and avian flu. (edit) |
| SARSr-CoV (edit) |
Roles of spike protein in the pathogenesis of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Routes of transmission of influenza A H1N1, SARS CoV, and norovirus in air cabin: Comparative analyses. (edit) |
| SARSr-CoV (edit) |
SARS CoV replication and pathogenesis in human airway epithelial cultures. (edit) |
| SARSr-CoV (edit) |
SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement (edit) |
| SARSr-CoV (edit) |
SARS Coronavirus Fusion Peptide-Derived Sequence Suppresses Collagen-Induced Arthritis in DBA/1J Mice (edit) |
| SARSr-CoV (edit) |
SARS Coronaviruses and Highly Pathogenic Influenza Viruses: Safety and Occupational Health for Laboratory Workers. (edit) |
| SARSr-CoV (edit) |
SARS and MERS: recent insights into emerging coronaviruses (edit) |
| SARSr-CoV (edit) |
SARS and common viral infections (edit) |
| SARSr-CoV (edit) |
SARS and other coronaviruses in humans and animals (edit) |
| SARSr-CoV (edit) |
SARS associated coronavirus has a recombinant polymerase and coronaviruses have a history of host-shifting (edit) |
| SARSr-CoV (edit) |
SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. (edit) |
| SARSr-CoV (edit) |
SARS coronavirus 8b reduces viral replication by down-regulating E via an ubiquitin-independent proteasome pathway. (edit) |
| SARSr-CoV (edit) |
SARS coronavirus and apoptosis. (edit) |
| SARSr-CoV (edit) |
SARS coronavirus and innate immunity (edit) |
| SARSr-CoV (edit) |
SARS coronavirus anti-infectives (edit) |
| SARSr-CoV (edit) |
SARS coronavirus detection methods. (edit) |
| SARSr-CoV (edit) |
SARS coronavirus detection. (edit) |
| SARSr-CoV (edit) |
SARS coronavirus induces apoptosis in Vero E6 cells (edit) |
| SARSr-CoV (edit) |
SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens (edit) |
| SARSr-CoV (edit) |
SARS coronavirus nucleocapsid protein monoclonal antibodies developed using a prokaryotic expressed protein. (edit) |
| SARSr-CoV (edit) |
SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-β1 via ROS/p38 MAPK/STAT3 pathway (edit) |
| SARSr-CoV (edit) |
SARS coronavirus papain-like protease up-regulates the collagen expression through non-Samd TGF-β1 signaling (edit) |
| SARSr-CoV (edit) |
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon (edit) |
| SARSr-CoV (edit) |
SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
SARS coronavirus without reservoir originated from an unnatural evolution, experienced the reverse evolution, and finally disappeared in the world (edit) |
| SARSr-CoV (edit) |
SARS coronavirus: a new challenge for prevention and therapy (edit) |
| SARSr-CoV (edit) |
SARS diagnosis, monitoring and prognostication by SARS-coronavirus RNA detection. (edit) |
| SARSr-CoV (edit) |
SARS genome chip available to scientists: the NIAID hopes that widespread access to the SARS genome chip will catalyse research into effective treatments for the virus. (edit) |
| SARSr-CoV (edit) |
SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity. (edit) |
| SARSr-CoV (edit) |
SARS transmission pattern in Singapore reassessed by viral sequence variation analysis (edit) |
| SARSr-CoV (edit) |
SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. (edit) |
| SARSr-CoV (edit) |
SARS veterans tackle coronavirus. (edit) |
| SARSr-CoV (edit) |
SARS viral RNA. (edit) |
| SARSr-CoV (edit) |
SARS virus identified, but the disease is still spreading. (edit) |
| SARSr-CoV (edit) |
SARS virus in tears? (edit) |
| SARSr-CoV (edit) |
SARS virus returns to China as scientists race to find effective vaccine. (edit) |
| SARSr-CoV (edit) |
SARS virus: the beginning of the unraveling of a new coronavirus (edit) |
| SARSr-CoV (edit) |
SARS--beginning to understand a new virus (edit) |
| SARSr-CoV (edit) |
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii (edit) |
| SARSr-CoV (edit) |
SARS-CoV ORF1b-encoded nonstructural proteins 12-16: replicative enzymes as antiviral targets. (edit) |
| SARSr-CoV (edit) |
SARS-CoV and IFN: Too Little, Too Late. (edit) |
| SARSr-CoV (edit) |
SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission (edit) |
| SARSr-CoV (edit) |
SARS-CoV antibody prevalence in all Hong Kong patient contacts (edit) |
| SARSr-CoV (edit) |
SARS-CoV genome polymorphism: a bioinformatics study (edit) |
| SARSr-CoV (edit) |
SARS-CoV heptad repeat 2 is a trimer of parallel helices. (edit) |
| SARSr-CoV (edit) |
SARS-CoV infection and pregnancy (edit) |
| SARSr-CoV (edit) |
SARS-CoV infection in a restaurant from palm civet (edit) |
| SARSr-CoV (edit) |
SARS-CoV infection was from at least two origins in the Taiwan area. (edit) |
| SARSr-CoV (edit) |
SARS-CoV nucleocapsid protein induced apoptosis of COS-1 mediated by the mitochondrial pathway (edit) |
| SARSr-CoV (edit) |
SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism (edit) |
| SARSr-CoV (edit) |
SARS-CoV protease inhibitors design using virtual screening method from natural products libraries (edit) |
| SARSr-CoV (edit) |
SARS-CoV regulates immune function-related gene expression in human monocytic cells. (edit) |
| SARSr-CoV (edit) |
SARS-CoV related Betacoronavirus and diverse Alphacoronavirus members found in western old-world. (edit) |
| SARSr-CoV (edit) |
SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells (edit) |
| SARSr-CoV (edit) |
SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium (edit) |
| SARSr-CoV (edit) |
SARS-CoV sampling from 3 portals. (edit) |
| SARSr-CoV (edit) |
SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus. (edit) |
| SARSr-CoV (edit) |
SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice. (edit) |
| SARSr-CoV (edit) |
SARS-CoV virus-host interactions and comparative etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of formalin-fixed paraffin-embedded tissues (edit) |
| SARSr-CoV (edit) |
SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry (edit) |
| SARSr-CoV (edit) |
SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology (edit) |
| SARSr-CoV (edit) |
SARS-CoV: Lessons for global health (edit) |
| SARSr-CoV (edit) |
SARS-Coronavirus ancestor's foot-prints in South-East Asian bat colonies and the refuge theory (edit) |
| SARSr-CoV (edit) |
SARS-associated coronavirus gene fragments were detected from a suspected pediatric SARS patient (edit) |
| SARSr-CoV (edit) |
SARS-associated coronavirus infection in teenagers. (edit) |
| SARSr-CoV (edit) |
SARS-associated coronavirus quasispecies in individual patients. (edit) |
| SARSr-CoV (edit) |
SARS-associated coronavirus replication in cell lines (edit) |
| SARSr-CoV (edit) |
SARS-associated coronavirus transmission, United States (edit) |
| SARSr-CoV (edit) |
SARS-associated coronavirus transmitted from human to pig (edit) |
| SARSr-CoV (edit) |
SARS-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases (edit) |
| SARSr-CoV (edit) |
SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation. (edit) |
| SARSr-CoV (edit) |
SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. (edit) |
| SARSr-CoV (edit) |
SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. (edit) |
| SARSr-CoV (edit) |
SARS-coronavirus replication in human peripheral monocytes/macrophages (edit) |
| SARSr-CoV (edit) |
SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro (edit) |
| SARSr-CoV (edit) |
SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion (edit) |
| SARSr-CoV (edit) |
SARS-like virus in the Middle East: a truly bat-related coronavirus causing human diseases (edit) |
| SARSr-CoV (edit) |
SARS-like virus reignites ownership feuds. (edit) |
| SARSr-CoV (edit) |
SARS-related virus predating SARS outbreak, Hong Kong (edit) |
| SARSr-CoV (edit) |
SARS-unique fold in the Rousettus bat coronavirus HKU9. (edit) |
| SARSr-CoV (edit) |
SARS: an amalgam of avian and mammalian viruses? (edit) |
| SARSr-CoV (edit) |
SARS: clinical virology and pathogenesis (edit) |
| SARSr-CoV (edit) |
SARS: just another viral acronym? (edit) |
| SARSr-CoV (edit) |
SARS: lessons learned from other coronaviruses. (edit) |
| SARSr-CoV (edit) |
SARS: responding to an unknown virus (edit) |
| SARSr-CoV (edit) |
SARS: understanding the coronavirus: accuracy of WHO criteria was similar in a "non-SARS" hospital in Singapore. (edit) |
| SARSr-CoV (edit) |
SARS: understanding the coronavirus: apoptosis may explain lymphopenia of SARS. (edit) |
| SARSr-CoV (edit) |
SARS: understanding the virus and development of rational therapy (edit) |
| SARSr-CoV (edit) |
Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. (edit) |
| SARSr-CoV (edit) |
Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease. (edit) |
| SARSr-CoV (edit) |
Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor. (edit) |
| SARSr-CoV (edit) |
Searching immunodominant epitopes prior to epidemic: HLA class II-restricted SARS-CoV spike protein epitopes in unexposed individuals. (edit) |
| SARSr-CoV (edit) |
Selection of SARS-coronavirus-specific B cell epitopes by phage peptide library screening and evaluation of the immunological effect of epitope-based peptides on mice (edit) |
| SARSr-CoV (edit) |
Self-assembly of a nine-residue amyloid-forming peptide fragment of SARS corona virus E-protein: mechanism of self aggregation and amyloid-inhibition of hIAPP. (edit) |
| SARSr-CoV (edit) |
Sensitive detection of SARS coronavirus RNA by a novel asymmetric multiplex nested RT-PCR amplification coupled with oligonucleotide microarray hybridization (edit) |
| SARSr-CoV (edit) |
Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans (edit) |
| SARSr-CoV (edit) |
Sequential affinity purification of peroxidase tagged bispecific anti-SARS-CoV antibodies on phenylboronic acid agarose (edit) |
| SARSr-CoV (edit) |
Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. (edit) |
| SARSr-CoV (edit) |
Seroepidemiological Study on SARS-CoV IgG Antibodies of Different Populations from Several Areas (edit) |
| SARSr-CoV (edit) |
Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. (edit) |
| SARSr-CoV (edit) |
Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. (edit) |
| SARSr-CoV (edit) |
Seroprevalence of SARS Coronavirus Among Residents Near a Hospital with a Nosocomial Outbreak. (edit) |
| SARSr-CoV (edit) |
Seroprevalence of SARS coronavirus antibody in household contacts. (edit) |
| SARSr-CoV (edit) |
Seroprevalence of antibody to severe acute respiratory syndrome (SARS)-associated coronavirus among health care workers in SARS and non-SARS medical wards. (edit) |
| SARSr-CoV (edit) |
Severe Acute Respiratory Syndrome (SARS) Coronavirus ORF8 Protein Is Acquired from SARS-Related Coronavirus from Greater Horseshoe Bats through Recombination (edit) |
| SARSr-CoV (edit) |
Severe Acute Respiratory Syndrome (SARS) and the GDP. Part I : Epidemiology, virology, pathology and general health issues. (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome (SARS) and coronavirus testing--United States, 2003. (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome (SARS) coronavirus. (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome (SARS) coronavirus: possible re-emergence of the Asian-global novel threat. (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome (SARS)--paradigm of an emerging viral infection. (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome (SARS): an old virus jumping into a new host or a new creation? (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. (edit) |
| SARSr-CoV (edit) |
Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group (edit) |
| SARSr-CoV (edit) |
Signal transduction in SARS-CoV-infected cells (edit) |
| SARSr-CoV (edit) |
Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference (edit) |
| SARSr-CoV (edit) |
Silencing of SARS-CoV spike gene by small interfering RNA in HEK 293T cells (edit) |
| SARSr-CoV (edit) |
Simultaneous detection of SARS coronavirus and influenza A viruses using real-time polymerase chain reaction. (edit) |
| SARSr-CoV (edit) |
Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model (edit) |
| SARSr-CoV (edit) |
Small interfering RNA effectively inhibits the expression of SARS coronavirus membrane gene at two novel targeting sites. (edit) |
| SARSr-CoV (edit) |
Small interfering RNA inhibits SARS-CoV nucleocapsid gene expression in cultured cells and mouse muscles (edit) |
| SARSr-CoV (edit) |
Solution structure of the X4 protein coded by the SARS related coronavirus reveals an immunoglobulin like fold and suggests a binding activity to integrin I domains (edit) |
| SARSr-CoV (edit) |
Stability and inactivation of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. (edit) |
| SARSr-CoV (edit) |
Stem-loop 1 in the 5' UTR of the SARS coronavirus can substitute for its counterpart in mouse hepatitis virus. (edit) |
| SARSr-CoV (edit) |
Structural analysis of inhibition mechanisms of aurintricarboxylic acid on SARS-CoV polymerase and other proteins. (edit) |
| SARSr-CoV (edit) |
Structural and biochemical basis for the difference in the helicase activity of two different constructs of SARS-CoV helicase. (edit) |
| SARSr-CoV (edit) |
Structural and biochemical investigation of heptad repeat derived peptides of human SARS corona virus (hSARS-CoV) spike protein (edit) |
| SARSr-CoV (edit) |
Structural and dynamic characterization of the interaction of the putative fusion peptide of the S2 SARS-CoV virus protein with lipid membranes. (edit) |
| SARSr-CoV (edit) |
Structural biology. Adaptation of SARS coronavirus to humans. (edit) |
| SARSr-CoV (edit) |
Structural insights into SARS coronavirus proteins (edit) |
| SARSr-CoV (edit) |
Structural insights of a self-assembling 9-residue peptide from the C-terminal tail of the SARS corona virus E-protein in DPC and SDS micelles: A combined high and low resolution spectroscopic study. (edit) |
| SARSr-CoV (edit) |
Structural organization of the genome of SARS-associated coronavirus (Strain SoD) isolated on the territory of the Russian Federation. (edit) |
| SARSr-CoV (edit) |
Structural proteomics of the SARS coronavirus: a model response to emerging infectious diseases (edit) |
| SARSr-CoV (edit) |
Structure based computational assessment of channel properties of assembled ORF-8a from SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Structure of a Conserved RNA Element in the SARS Virus Genome Determined (edit) |
| SARSr-CoV (edit) |
Structure of a SARS coronavirus-derived peptide bound to the human major histocompatibility complex class I molecule HLA-B*1501 (edit) |
| SARSr-CoV (edit) |
Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors (edit) |
| SARSr-CoV (edit) |
Structure-based preliminary analysis of immunity and virulence of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits. (edit) |
| SARSr-CoV (edit) |
Studies explore impact of new pathogens: investigators report on metapneumovirus, SARS. (edit) |
| SARSr-CoV (edit) |
Studies of SARS virus vaccines (edit) |
| SARSr-CoV (edit) |
Study on interaction between SARS-CoV N and MAP19 (edit) |
| SARSr-CoV (edit) |
Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. (edit) |
| SARSr-CoV (edit) |
Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody (edit) |
| SARSr-CoV (edit) |
Substrate specificity and rational design of peptidomimetic inhibitors for SARS coronavirus main protease (edit) |
| SARSr-CoV (edit) |
Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein (edit) |
| SARSr-CoV (edit) |
Surface ultrastructure of SARS coronavirus revealed by atomic force microscopy. (edit) |
| SARSr-CoV (edit) |
Surface vimentin is critical for the cell entry of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
Susceptibility of different eukaryotic cell lines to SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Susceptibility of human and rat neural cell lines to infection by SARS-coronavirus (edit) |
| SARSr-CoV (edit) |
Susceptibility of pigs and chickens to SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor (edit) |
| SARSr-CoV (edit) |
Symptoms of infection caused by SARS coronavirus in laboratory mice and guinea pigs. (edit) |
| SARSr-CoV (edit) |
Synergistic inhibition of SARS-coronavirus replication by type I and type II IFN. (edit) |
| SARSr-CoV (edit) |
Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications (edit) |
| SARSr-CoV (edit) |
Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase (edit) |
| SARSr-CoV (edit) |
Synthesis and antiviral evaluation of 7-O-arylmethylquercetin derivatives against SARS-associated coronavirus (SCV) and hepatitis C virus (HCV). (edit) |
| SARSr-CoV (edit) |
Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents. (edit) |
| SARSr-CoV (edit) |
Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. (edit) |
| SARSr-CoV (edit) |
Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor (edit) |
| SARSr-CoV (edit) |
Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors. (edit) |
| SARSr-CoV (edit) |
Synthesis of cyclopentenyl carbocyclic nucleosides as potential antiviral agents against orthopoxviruses and SARS. (edit) |
| SARSr-CoV (edit) |
Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS). (edit) |
| SARSr-CoV (edit) |
Synthesis of stilbene derivatives with inhibition of SARS coronavirus replication. (edit) |
| SARSr-CoV (edit) |
Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor (edit) |
| SARSr-CoV (edit) |
Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease. (edit) |
| SARSr-CoV (edit) |
Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors. (edit) |
| SARSr-CoV (edit) |
Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: perspective for SARS vaccine development (edit) |
| SARSr-CoV (edit) |
Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A*0201 transgenic mice (edit) |
| SARSr-CoV (edit) |
Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. (edit) |
| SARSr-CoV (edit) |
Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus (edit) |
| SARSr-CoV (edit) |
Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice (edit) |
| SARSr-CoV (edit) |
T cell responses to whole SARS coronavirus in humans (edit) |
| SARSr-CoV (edit) |
T-Cell response profiling to biological threat agents including the SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. (edit) |
| SARSr-CoV (edit) |
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. (edit) |
| SARSr-CoV (edit) |
TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds (edit) |
| SARSr-CoV (edit) |
TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection. (edit) |
| SARSr-CoV (edit) |
Tears and conjunctival scrapings for coronavirus in patients with SARS. (edit) |
| SARSr-CoV (edit) |
Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus. (edit) |
| SARSr-CoV (edit) |
Ten years after SARS: where was the virus from? (edit) |
| SARSr-CoV (edit) |
Tertiary structure prediction of SARS coronavirus helicase. (edit) |
| SARSr-CoV (edit) |
Testing the hypothesis of a recombinant origin of the SARS-associated coronavirus. (edit) |
| SARSr-CoV (edit) |
The C-terminal portion of the nucleocapsid protein demonstrates SARS-CoV antigenicity (edit) |
| SARSr-CoV (edit) |
The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus. (edit) |
| SARSr-CoV (edit) |
The H7N9 influenza virus in China--changes since SARS. (edit) |
| SARSr-CoV (edit) |
The R protein of SARS-CoV: analyses of structure and function based on four complete genome sequences of isolates BJ01-BJ04 (edit) |
| SARSr-CoV (edit) |
The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis. (edit) |
| SARSr-CoV (edit) |
The SARS coronavirus E protein interacts with the PALS1 and alters tight junction formation and epithelial morphogenesis. (edit) |
| SARSr-CoV (edit) |
The SARS coronavirus nucleocapsid protein--forms and functions. (edit) |
| SARSr-CoV (edit) |
The SARS coronavirus: rapid diagnostics in the limelight. (edit) |
| SARSr-CoV (edit) |
The SARS-CoV ferret model in an infection-challenge study. (edit) |
| SARSr-CoV (edit) |
The SARS-CoV heptad repeat 2 exhibits pH-induced helix formation. (edit) |
| SARSr-CoV (edit) |
The SARS-like coronaviruses: the role of bats and evolutionary relationships with SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
The SR-rich motif in SARS-CoV nucleocapsid protein is important for virus replication. (edit) |
| SARSr-CoV (edit) |
The Severe Acute Respiratory Syndrome (SARS)-coronavirus 3a protein may function as a modulator of the trafficking properties of the spike protein (edit) |
| SARSr-CoV (edit) |
The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
The antiviral action of common household disinfectants and antiseptics against murine hepatitis virus, a potential surrogate for SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein. (edit) |
| SARSr-CoV (edit) |
The design and application of DNA chips for early detection of SARS-CoV from clinical samples. (edit) |
| SARSr-CoV (edit) |
The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. (edit) |
| SARSr-CoV (edit) |
The dimer interface of the SARS coronavirus nucleocapsid protein adapts a porcine respiratory and reproductive syndrome virus-like structure. (edit) |
| SARSr-CoV (edit) |
The effect of SARS coronavirus on blood system: its clinical findings and the pathophysiologic hypothesis (edit) |
| SARSr-CoV (edit) |
The effect of inhibition of PP1 and TNFα signaling on pathogenesis of SARS coronavirus (edit) |
| SARSr-CoV (edit) |
The epitope study on the SARS-CoV nucleocapsid protein. (edit) |
| SARSr-CoV (edit) |
The expression of SARS-CoV M gene in P. Pastoris and the diagnostic utility of the expression product. (edit) |
| SARSr-CoV (edit) |
The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. (edit) |
| SARSr-CoV (edit) |
The financial impact of controlling a respiratory virus outbreak in a teaching hospital: lessons learned from SARS. (edit) |
| SARSr-CoV (edit) |
The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8⁺ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848. (edit) |
| SARSr-CoV (edit) |
The immunity induced by recombinant spike proteins of SARS coronavirus in Balb/c mice. (edit) |
| SARSr-CoV (edit) |
The interaction of the SARS coronavirus non-structural protein 10 with the cellular oxido-reductase system causes an extensive cytopathic effect (edit) |
| SARSr-CoV (edit) |
The large 386-nt deletion in SARS-associated coronavirus: evidence for quasispecies? (edit) |
| SARSr-CoV (edit) |
The management of coronavirus infections with particular reference to SARS. (edit) |
| SARSr-CoV (edit) |
The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease (edit) |
| SARSr-CoV (edit) |
The nsp2 proteins of mouse hepatitis virus and SARS coronavirus are dispensable for viral replication (edit) |
| SARSr-CoV (edit) |
The nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha. (edit) |
| SARSr-CoV (edit) |
The nucleocapsid protein of the SARS coronavirus is capable of self-association through a C-terminal 209 amino acid interaction domain (edit) |
| SARSr-CoV (edit) |
The phylogeny of SARS coronavirus (edit) |
| SARSr-CoV (edit) |
The replication of a mouse adapted SARS-CoV in a mouse cell line stably expressing the murine SARS-CoV receptor mACE2 efficiently induces the expression of proinflammatory cytokines (edit) |
| SARSr-CoV (edit) |
The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis (edit) |
| SARSr-CoV (edit) |
The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis (edit) |
| SARSr-CoV (edit) |
The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice. (edit) |
| SARSr-CoV (edit) |
The secret life of ACE2 as a receptor for the SARS virus. (edit) |
| SARSr-CoV (edit) |
The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5' to 3' viral helicases. (edit) |
| SARSr-CoV (edit) |
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 (edit) |
| SARSr-CoV (edit) |
The spike protein of SARS-CoV--a target for vaccine and therapeutic development (edit) |
| SARSr-CoV (edit) |
The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells (edit) |
| SARSr-CoV (edit) |
The structural characterization and antigenicity of the S protein of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
The structure analysis and antigenicity study of the N protein of SARS-CoV. (edit) |
| SARSr-CoV (edit) |
The structure of a rigorously conserved RNA element within the SARS virus genome (edit) |
| SARSr-CoV (edit) |
Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy (edit) |
| SARSr-CoV (edit) |
Thermostability of the N-terminal RNA-binding domain of the SARS-CoV nucleocapsid protein: experiments and numerical simulations (edit) |
| SARSr-CoV (edit) |
Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. (edit) |
| SARSr-CoV (edit) |
Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells. (edit) |
| SARSr-CoV (edit) |
Toona sinensis Roem tender leaf extract inhibits SARS coronavirus replication. (edit) |
| SARSr-CoV (edit) |
Topographic changes in SARS coronavirus-infected cells at late stages of infection (edit) |
| SARSr-CoV (edit) |
Towards our understanding of SARS-CoV, an emerging and devastating but quickly conquered virus (edit) |
| SARSr-CoV (edit) |
Tracing SARS-coronavirus variant with large genomic deletion. (edit) |
| SARSr-CoV (edit) |
Tracing the SARS-coronavirus (edit) |
| SARSr-CoV (edit) |
Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays (edit) |
| SARSr-CoV (edit) |
Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication (edit) |
| SARSr-CoV (edit) |
Transcriptional profiling of Vero E6 cells over-expressing SARS-CoV S2 subunit: insights on viral regulation of apoptosis and proliferation (edit) |
| SARSr-CoV (edit) |
Transient oligomerization of the SARS-CoV N protein--implication for virus ribonucleoprotein packaging. (edit) |
| SARSr-CoV (edit) |
Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. (edit) |
| SARSr-CoV (edit) |
Travel implications of emerging coronaviruses: SARS and MERS-CoV. (edit) |
| SARSr-CoV (edit) |
Tryptophan-dependent membrane interaction and heteromerization with the internal fusion peptide by the membrane proximal external region of SARS-CoV spike protein. (edit) |
| SARSr-CoV (edit) |
Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). (edit) |
| SARSr-CoV (edit) |
Two strains of the SARS virus sequenced. (edit) |
| SARSr-CoV (edit) |
Two-amino acids change in the nsp4 of SARS coronavirus abolishes viral replication (edit) |
| SARSr-CoV (edit) |
Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein (edit) |
| SARSr-CoV (edit) |
Tyrosine dephosphorylation of STAT3 in SARS coronavirus-infected Vero E6 cells (edit) |
| SARSr-CoV (edit) |
Ultrastructure of SARS-CoV, FIPV, and MHV revealed by electron cryomicroscopy. (edit) |
| SARSr-CoV (edit) |
Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks - Implications for coronavirus vaccine development (edit) |
| SARSr-CoV (edit) |
Understanding the T cell immune response in SARS coronavirus infection (edit) |
| SARSr-CoV (edit) |
Unique SARS-CoV protein nsp1: bioinformatics, biochemistry and potential effects on virulence (edit) |
| SARSr-CoV (edit) |
Unraveling the complexities of the interferon response during SARS-CoV infection (edit) |
| SARSr-CoV (edit) |
Update on SARS research and other possibly zoonotic coronaviruses (edit) |
| SARSr-CoV (edit) |
Use of dual TaqMan probes to increase the sensitivity of 1-step quantitative reverse transcription-PCR: application to the detection of SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
Using patient-collected clinical samples and sera to detect and quantify the severe acute respiratory syndrome coronavirus (SARS-CoV). (edit) |
| SARSr-CoV (edit) |
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque (edit) |
| SARSr-CoV (edit) |
Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV) (edit) |
| SARSr-CoV (edit) |
Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses (edit) |
| SARSr-CoV (edit) |
Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants (edit) |
| SARSr-CoV (edit) |
Viral aetiology of acute respiratory illnesses in patients with a suspicion of severe acute respiratory syndrome (SARS) in Switzerland. (edit) |
| SARSr-CoV (edit) |
Viral evolution and the emergence of SARS coronavirus (edit) |
| SARSr-CoV (edit) |
Viral load and outcome in SARS infection: the role of personal protective equipment in the emergency department. (edit) |
| SARSr-CoV (edit) |
Viral load distribution in SARS outbreak (edit) |
| SARSr-CoV (edit) |
Viral load quantitation of SARS-coronavirus RNA using a one-step real-time RT-PCR. (edit) |
| SARSr-CoV (edit) |
Viral loads in clinical specimens and SARS manifestations. (edit) |
| SARSr-CoV (edit) |
Viral pathogens and acute lung injury: investigations inspired by the SARS epidemic and the 2009 H1N1 influenza pandemic (edit) |
| SARSr-CoV (edit) |
Virology. Researchers tie deadly SARS virus to bats. (edit) |
| SARSr-CoV (edit) |
Virology. The SARS coronavirus: a postgenomic era. (edit) |
| SARSr-CoV (edit) |
Virology: SARS virus infection of cats and ferrets. (edit) |
| SARSr-CoV (edit) |
Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. (edit) |
| SARSr-CoV (edit) |
Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. (edit) |
| SARSr-CoV (edit) |
Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. (edit) |
| SARSr-CoV (edit) |
Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. (edit) |
| SARSr-CoV (edit) |
Virus Infection and Titration of SARS-CoV in Mouse Lung (edit) |
| SARSr-CoV (edit) |
Virus detectives seek source of SARS in China's wild animals. (edit) |
| SARSr-CoV (edit) |
Virus-associated hemophagocytic syndrome in an international traveler as a differential diagnosis of SARS. (edit) |
| SARSr-CoV (edit) |
Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells (edit) |
| SARSr-CoV (edit) |
Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital (edit) |
| SARSr-CoV (edit) |
Vitamin C and SARS coronavirus. (edit) |
| SARSr-CoV (edit) |
When animal viruses attack: SARS and avian influenza. (edit) |
| SARSr-CoV (edit) |
Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions. (edit) |
| SARSr-CoV (edit) |
Why viral (SARS, Ebola and AIDS) epidemics now? (edit) |
| SARSr-CoV (edit) |
Yeast based small molecule screen for inhibitors of SARS-CoV (edit) |
| SARSr-CoV (edit) |
Yeast expression and characterization of SARS-CoV N protein. (edit) |
| SARSr-CoV (edit) |
Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate (edit) |
| SARSr-CoV (edit) |
ZCURVE_CoV: a new system to recognize protein coding genes in coronavirus genomes, and its applications in analyzing SARS-CoV genomes. (edit) |
| SARSr-CoV (edit) |
[A novel coronavirus---SARS virus]. (edit) |
| SARSr-CoV (edit) |
[A preliminary study of the structure prediction and expression of SARS-CoV spike protein]. (edit) |
| SARSr-CoV (edit) |
[A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it]. (edit) |
| SARSr-CoV (edit) |
[Amplification and cloning of the N gene of SARS-associated coronavirus]. (edit) |
| SARSr-CoV (edit) |
[An epidemiological investigation of bats carrying SARS-CoV in Guangzhou and its vicinity]. (edit) |
| SARSr-CoV (edit) |
[Analysis of false-positive associated with antibody tests for SARS-CoV in SLE patients]. (edit) |
| SARSr-CoV (edit) |
[Analysis on the SARS-CoV genome of PUMC01 isolate]. (edit) |
| SARSr-CoV (edit) |
[Antigenicity characterization of six different fragments of SARS-CoV N protein expressed in E. coli]. (edit) |
| SARSr-CoV (edit) |
[Clinical detection of polymerase gene of SARS-associated coronavirus]. (edit) |
| SARSr-CoV (edit) |
[Cloning of ACE-2 gene encoding the functional receptor for the SARS coronavirus and its expression in eukaryotic cells]. (edit) |
| SARSr-CoV (edit) |
[Cloning, expression and purification of SARS coronavirus PUMC2 strain nucleocapsid protein]. (edit) |
| SARSr-CoV (edit) |
[Cloning, purification, and antigenic characterization of three recombinant fragments derived from SARS-CoV S1 domain]. (edit) |
| SARSr-CoV (edit) |
[Comparison of serum biochemical features between SARS and other viral pneumonias]. (edit) |
| SARSr-CoV (edit) |
[Conditions for SARS-CoV cultivation and inactivation]. (edit) |
| SARSr-CoV (edit) |
[Construction and screening of human phage antibody library against SARS virus]. (edit) |
| SARSr-CoV (edit) |
[Detection of SARS coronavirus RNA]. (edit) |
| SARSr-CoV (edit) |
[Detection of SARS-CoV RNA in stool samples of SARS patients by nest RT-PCR and its clinical value]. (edit) |
| SARSr-CoV (edit) |
[Detection of SARS-associated coronavirus N protein by time-resolved fluoroimmunoassay]. (edit) |
| SARSr-CoV (edit) |
[Detection of SARS-coronavirus in both human and animals by RT-PCR]. (edit) |
| SARSr-CoV (edit) |
[Detection of the anti-SARS-coronavirus specific antibody levels in 156 SARS patients]. (edit) |
| SARSr-CoV (edit) |
[Detection of the mRNA expression of human angiotensin-converting enzyme 2 as a SARS coronavirus functional receptor in human femoral head]. (edit) |
| SARSr-CoV (edit) |
[Determination of SARS-CoV by simplified nested fluorescent RT-PCR]. (edit) |
| SARSr-CoV (edit) |
[Development and application of a safe SARS-CoV neutralization assay based on lentiviral vectors pseudotyped with SARS-CoV spike protein]. (edit) |
| SARSr-CoV (edit) |
[Development of monoclonal antibodies against SARS-CoV and identification of antigenic epitopes]. (edit) |
| SARSr-CoV (edit) |
[Development of the cDNA chip for SARS virus and a primary study on the possible molecular mechanism of interferon alpha2b inhibiting the SARS virus replication]. (edit) |
| SARSr-CoV (edit) |
[Effect of SARS-associated coronavirus on peripheral blood picture and liver function]. (edit) |
| SARSr-CoV (edit) |
[Enhanced-real time PCR: a highly sensitive method for SARS-coronavirus detection]. (edit) |
| SARSr-CoV (edit) |
[Expression of SARS coronavirus nucleocapsid protein and construction of its DNA vaccine]. (edit) |
| SARSr-CoV (edit) |
[Expression of SARS-CoV in various types of cells in lung tissues]. (edit) |
| SARSr-CoV (edit) |
[Expression of predicted B cell epitope peptide in S2 subunit of SARS coronavirus spike protein in E.coli and identification of its mimic antigenicity]. (edit) |
| SARSr-CoV (edit) |
[Expression, purification and antibody preparation of recombinat SARS-CoV X5 protein]. (edit) |
| SARSr-CoV (edit) |
[Expression, purification and identification of recombinant SARS coronavirus membrane protein]. (edit) |
| SARSr-CoV (edit) |
[Follow up study on viruses associated with SARS among the SARS patients]. (edit) |
| SARSr-CoV (edit) |
[Gene prediction and function research of SARS-CoV(BJ01)]. (edit) |
| SARSr-CoV (edit) |
[Gene sequence analysis of SARS-associated coronavirus by nested RT-PCR]. (edit) |
| SARSr-CoV (edit) |
[Genetic variation analysis of SARS coronavirus]. (edit) |
| SARSr-CoV (edit) |
[High-efficiency expression of a receptor-binding domain of SARS-CoV spike protein in tobacco chloroplasts]. (edit) |
| SARSr-CoV (edit) |
[Initial analysis of complete genome sequences of SARS coronavirus]. (edit) |
| SARSr-CoV (edit) |
[Modeling of the SARS coronavirus main proteinase and conformational flexibility of the active site]. (edit) |
| SARSr-CoV (edit) |
[Modified molecular beacon-based dual real-time PCR for detection of SARS virus and its application]. (edit) |
| SARSr-CoV (edit) |
[Optimization of expression condition of SARS-CoV PUPs genes in E. coli]. (edit) |
| SARSr-CoV (edit) |
[Over-expression in Escherichia coli and purification of nucleocaspid and membrane protein of SARS coronavirus]. (edit) |
| SARSr-CoV (edit) |
[Preparation of specific monoclonal antibody against nucleocapsid protein of SARS coronavirus]. (edit) |
| SARSr-CoV (edit) |
[Prokaryotic expression of SARS coronavirus spike protein and construction of its DNA vaccine]. (edit) |
| SARSr-CoV (edit) |
[RNase III-prepared short interfering RNAs induce degradation of SARS-coronavirus mRNAs in human cells]. (edit) |
| SARSr-CoV (edit) |
[SARS coronavirus]. (edit) |
| SARSr-CoV (edit) |
[SARS: a new paramyxovirus or coronavirus?]. (edit) |
| SARSr-CoV (edit) |
[Serological analysis of SARS Coronavirus in children diagnosed clinically as severe acute respiratory syndrome cases during SARS epidemic in Beijing]. (edit) |
| SARSr-CoV (edit) |
[Some medical staff positive for serum SARS coronavirus antibody IgG have only mild symptoms]. (edit) |
| SARSr-CoV (edit) |
[Study on the RNA of severe acute respiratory syndrome (SARS) associated coronavirus in the blood and excretion of convalescent patients with SARS]. (edit) |
| SARSr-CoV (edit) |
[Study on the changing regularity of special antibody and expression of stomach and enteric involvement on SARS-coronavirus infection in the recovery period of severe acute respiratory syndrome]. (edit) |
| SARSr-CoV (edit) |
[The biological characteristics of SARS virus and its related coronaviruses]. (edit) |
| SARSr-CoV (edit) |
[The cloning, expression, purification and identification of SARS virus S2 gene and study on its immunological characteristics]. (edit) |
| SARSr-CoV (edit) |
[The expression and activity detection of a variant N protein of SARS-CoV]. (edit) |
| SARSr-CoV (edit) |
[The genome comparison of SARS-CoV and other coronaviruses]. (edit) |
| SARSr-CoV (edit) |
[Variability analysis of S2 gene of SARS-CoV]. (edit) |
| SARSr-CoV (edit) |
[cDNAs cloning of SARS-CoV PUMC2 viral genome]. (edit) |
| SARSr-CoV (edit) |
siRNA targeting the leader sequence of SARS-CoV inhibits virus replication. (edit) |
| SARSr-CoV (edit) |
siRNAs targeting terminal sequences of the SARS-associated coronavirus membrane gene inhibit M protein expression through degradation of M mRNA. (edit) |
| human Coronavirus NL63 (edit) |
Attachment factor and receptor engagement of SARS coronavirus and human coronavirus NL63. (edit) |
| human Coronavirus NL63 (edit) |
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses (edit) |
| human Coronavirus NL63 (edit) |
Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, Japan (edit) |
| human Coronavirus NL63 (edit) |
Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. (edit) |
| human Coronavirus NL63 (edit) |
Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients (edit) |
| human Coronavirus NL63 (edit) |
Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China (edit) |
| human Coronavirus NL63 (edit) |
Increased Incidence, Morbidity, and Mortality in Human Coronavirus NL63 Associated with ACE Inhibitor Therapy and Implication in SARS-CoV-2 (COVID-19) (edit) |
| human Coronavirus NL63 (edit) |
Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. (edit) |
| human Coronavirus NL63 (edit) |
Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection (edit) |
| human Coronavirus NL63 (edit) |
Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease (edit) |
| human Coronavirus NL63 (edit) |
Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. (edit) |
| human Coronavirus NL63 (edit) |
SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells (edit) |
| human Coronavirus NL63 (edit) |
SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry (edit) |
| human Coronavirus NL63 (edit) |
The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. (edit) |
| human Coronavirus NL63 (edit) |
The novel human coronaviruses NL63 and HKU1. (edit) |
| human Coronavirus NL63 (edit) |
[Development and comparison of real-time and conventional RT-PCR assay for detection of human coronavirus NL63 and HKU1]. (edit) |
This SPARQL query is available under CCZero.